UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
x ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the fiscal year ended: September 30, 2015
o TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission
file number: 000-54672
American
CryoStem Corporation
(Exact
name of registrant as specified in its charter)
Nevada |
|
26-4574088 |
(State
or other jurisdiction of incorporation
or organization) |
|
(I.R.S.
Employer Identification No.) |
1
Meridian Road, Suite 5
Eatontown,
NJ 07724 |
(Address
of principal executive offices) |
(732)
747-1007 |
(Registrant’s
telephone number, including area code) |
Securities
registered pursuant to Section 12(b) of the Act: None
Securities
registered pursuant to Section 12(g) of the Act: Class A Common Stock, par value $0.001
Indicate
by checkmark if registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No o
Indicate
by checkmark if registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes
o No o
Indicate
by checkmark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of the Registrant’s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting
company. See definition of “large accelerated filer”, “accelerated filer”, and “smaller reporting
company” in Rule 12b-2 of the Exchange Act.
Large
Accelerated Filer |
o |
Accelerated
Filer |
o |
Non-Accelerated
Filer |
o |
Smaller
reporting company |
x |
Indicate
by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Act). Yes o No x
The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based on a closing
price of $.0.48 on March 31, 2015 (the last business day of the registrants most recently completed second fiscal quarter)
was approximately $6,578,616
As
of January 8, 2016, the registrant had 34,705,451 shares of its common stock, par value $0.001, outstanding.
TABLE
OF CONTENTS
FORWARD
LOOKING STATEMENTS
Included
in this Form 10-K are “forward-looking” statements, as well as historical information. Although we believe that
the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that the expectations reflected
in these forward-looking statements will prove to be correct. Our actual results could differ materially from those anticipated
in forward-looking statements as a result of certain factors, including matters described in the section titled “Risk Factors.”
Forward-looking statements include those that use forward-looking terminology, such as the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “project,” “plan,”
“will,” “shall,” “should,” and similar expressions, including when used in the negative. Although
we believe that the expectations reflected in these forward-looking statements are reasonable and achievable, these statements
involve risks and uncertainties and we cannot assure you that actual results will be consistent with these forward-looking statements.
We undertake no obligation to update or revise these forward-looking statements, whether to reflect events or circumstances after
the date initially filed or published, to reflect the occurrence of unanticipated events or otherwise.
PART
I
Item 1.
Business.
Company
Overview
History
We
were incorporated in the state of Nevada on March 13, 2009. On April 20, 2011, we acquired, through our wholly owned subsidiary
American CryoStem Acquisition Corporation, substantially all of the assets from, and assumed substantially all of the liabilities
of, ACS Global, Inc. (“ACS”) in exchange for our issuance of 21,000,000 shares of our common stock, par value $0.001
per share, to ACS (the “Asset Purchase”). We filed a Current Report on Form 8-K with the Securities and Exchange Commission
(SEC) on April 27, 2011 disclosing the Asset Purchase and certain related matters including, but not limited to, the appointment
of our present officers and directors as well as the resignation by the former chief executive officer and sole director. Our
fiscal year ends September 30 of each calendar year.
Upon
the closing of the Asset Purchase: (i) ACS Global became our majority shareholder, (ii) John Arnone was appointed as our chief
executive officer and president and Anthony Dudzinski was appointed as our chief operating officer, treasurer and secretary, and
(iii) John Arnone and Anthony Dudzinski were appointed to our board of directors, with Mr. Arnone being appointed as Chairman
of the Board. Mr. Dudzinski is also a director and the president and treasurer of ACS Global and Mr. Arnone is a director and
secretary of ACS Global. Contemporaneously with the Asset Purchase Closing, we sold 1,860,000 shares of Common Stock to accredited
investors in a private placement at a purchase price of $0.50 per share for aggregate gross proceeds of $930,000.
Our
Business
American
CryoStem Corporation is a biotechnology pioneer in the field of Regenerative and Personalized Medicine and operates a state-of-the-art,
FDA-registered, clinical laboratory dedicated to our standardized processing, bio-banking and development of cellular tools and
applications using autologous adipose (fat) tissue and adipose derived stem cells (“ADSCs”). The Company
has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating processes that
form its core standardized cellular platform which we believe supports and promotes a growing pipeline of biologic products and
processes, clinical services and international licensing opportunities. Our FDA registered clinical laboratory which we believe
to be in compliance with FDA regulations for human tissue processing, cryro-storage and cell culture and differentiation media
development is located in Mount Laurel, New Jersey at the Burlington County College Science Incubator.
The
Company believes the reproducibility of scientific studies has become a substantial issue in life science research from drug discovery
and development through clinical trials as researchers throughout the world continue to use different protocols for processes
associated with sample preparation, cryopreservation and cold chain management. We believe the scientific community is becoming
more aware of factors that affect sample integrity and experimental variability. By standardizing handling, storage, and transportation
protocols we can substantially improve the quality and reproducibility of preclinical and clinical data which will help to accelerate
the transition from lab research to drug and therapy development and market launch. To this end, we have licensed affiliates
operating on our cellular collection-processing and storage platform in Tokyo, Japan, and Hong Kong. Our licensees purchase our
CELLECT® adipose tissue collection kits and ACSelerate-CP™ storage consumables from us.
Our
business strategy is centered on marketing our standardized platform as a complete adipose stem cell solution and expanding our
research and development through scientific collaborations. We intend to generate revenue through the sale and licensing of our
patented products, laboratory tools, and services to attempt to capitalize on: (1) ADSC technologies; (2) scientific breakthroughs
incorporating ADSCs that have been developing in the fast growing Regenerative and Personalized Medicine industries; (3) providing
these growth industries with a standardized ADSC cell processing platform; (4) enhancing the delivery of healthcare through cellular-based
therapies and applications which address disease treatment, wound and burn healing, joint repair and personalized health and beauty
care; and (5) building a global network of physicians and affiliated laboratory facilities for the delivery of our products and
services.
Our
proprietary, patent pending clinical processing platform allows for the collection, preparation and cryo-preservation of adipose
tissue without manipulation, bio-generation or the addition of animal-derived products or other chemical materials which require
removal from the tissue sample upon retrieval or prior to use. Management believes this core process makes each tissue sample
suitable for use in cosmetic grafting procedures or for further processing to adult stem cells for other types of stem cell therapies.
Currently, we believe there are numerous therapeutic and orthopedic applications for adipose tissue and adult stem cell treatments
identified or in use globally. As of January 1, 2016, a review of clinicaltrials.gov, operated by the US National Institutes of
Health (NIH) indicates that there is a significant number of clinical trials registered or completed that are focused on adipose
tissue (1776), adult stem cells (5165), adipose derived stem cells (155), mesenchymal stem cells (575), and stromal vascular fraction
(33).
![acryo001_v1](http://www.sec.gov/Archives/edgar/data/1468679/000101905616000990/acryo001_v1.jpg)
Products
and Services
American
CryoStem is focused on multiple high margin business lines capable of generating sustainable, recurring revenue streams from each
of our developed products and services. The Company also incorporates its proprietary and patented or patent pending laboratory
products, such as our ACSelerate™ cell culture media, into our processing product production and contract
manufacturing services. Additionally, the Company may require licensees of our tissue and cell processing technologies to purchase
all the consumable products required in the collection, processing and storage of tissue/stem cells as part of the licensing agreement.
To
date, we have generated minimal revenue; however, subject to, among other factors, obtaining the requisite financing, management
believes that we are well positioned to leverage our developed products and services as the basis for international distribution
through licensees of our technologies and a host of Regenerative Medicine uses and future applications.
The
following products and services are designed to become the basis of, or an integral part of, planned licensing territories, revenue
generating, and cellular therapy development activities: Our products and services are:
· |
CELLECT® |
· |
Patent Pending PCT/US2011-39260 Tissue Collection and transportation system designed for physicians to facilitate the collection and overnight shipping of an individual’s adipose tissue to our FDA registered laboratory; |
|
|
· |
CELLECT® transportation system is used for all American CryoStem adipose tissue processing services ATGRAFT™, ATCELL™, contract manufacturing services. |
|
|
· |
Manufacture and sale of our CELLECT® collection system to licensees for our ATGRAFT™ and ATCELL™ technologies. |
|
|
· |
Proprietary transportation methodology utilizing our patent pending ACSelerate™-TR Transportation Medium for shipping adipose tissue at ambient temperature. |
|
|
|
|
· |
ATGRAFT™ |
· |
Patent pending PCT/US13/44621 adipose tissue processing at our Laboratory and preparation for long term storage of cleaned, whole fat for fat transfer procedures and future reprocessing into cellular applications. |
|
|
· |
Multiple storage configuration sizes (4mL, 5mL, 50mL & 100mL) allow for maximum fat storage and transfer flexibility. |
|
|
· |
ATGRAFT™ is stored in a DMSO free cryoprotectant which requires no further processing by a physician upon retrieval of a patient’s sample. |
|
|
· |
Licensing of the ATGRAFT™ processing technology to international partners utilizing our CELLECT® collection boxes and ACSelerate™ mediums. |
|
|
|
|
· |
ATCELL™ |
· |
Patent pending #13/646,676 for the processing and isolation of cellular specific components of an individual’s adipose tissue to create adipose derived stem cell (ADSCs) lines for storage, expansion, or differentiation. |
|
|
· |
Proprietary processing methodologies of ATCELL™ have been confirmed to be 96%+ pure ADSCs by third party flow cytometry. |
|
|
· |
IRB approved process as of June 2013. |
|
|
· |
Clinical and Research grade ATCELL™ lines for use with or sale to collaborative partners in research and application development and optimization, cell morphology and characterization assays, and growth analysis. |
|
|
|
|
· |
ACSELERATE™ |
· |
Patented #7,989,205 with continuation filed 313,194,900 Cell media line for transporting, expanding, differentiating and storing human cells. |
|
|
· |
Specially optimized for used with adipose tissue and adipose derived stem cells. |
|
|
· |
Superior growth and differentiation capabilities compared to industry competitors. |
|
|
· |
Used exclusively in all American CryoStem processing (ATGRAFT™, ATCELL™ and contract manufacturing). |
|
|
|
|
· |
ACS Laboratories™ |
· |
Manufacturing and sale of our patented ACSelerate™ cell culture media products. |
|
|
· |
Creation and sale of research grade ATCELL™ |
|
|
· |
Participation and support of all collaborative research projects |
|
|
· |
Contract manufacturing, including Autokine-CM® |
|
|
· |
Provide testing services for physicians performing in-office procedures and tissue processing |
|
|
|
|
· |
International Licensing |
· |
Standard Operating Procedures (SOPs) and all associated components and products |
|
|
· |
Consulting and Marketing Review and Assessment |
|
|
· |
CELLECT® (consumable) |
|
|
· |
ATGRAFT™ (consumable) |
|
|
· |
ATCELL™ (consumable) |
|
|
· |
Adipose tissue processing, cellular expansion and product manufacture |
CELLECT®
Validated Collection, Transportation, and Storage System – An unbreakable “chain of custody” clinical
solution for physicians to collect and deliver tissue samples utilizing proprietary and patent pending methods and materials.
The CELLECT® service is monitored in real-time and assures the highest cell viability upon laboratory receipt.
The CELLECT® system incorporates our ACSelerate–TR transport medium into all collection bags which supports
the health of the tissue during transport. The CELLECT® kit is an integral part of our validated ATGRAFT™
and ATCELL™ technology to be used by all licensees of our technologies. The CELLECT® service
is included in our pending patent application U.S. Serial No. 13/702,304.
American
CryoStem is the first tissue bank to globally incorporate through its CELLECT® service the International
Blood Banking identification and labeling and product identification coding system. The coding was developed in conjunction with
the American Association of Blood Banks (AABB), the American Red Cross and the International Society of Blood Transfusion (ISBT).
These groups formed the International Council for Commonality in Blood Banking Automation (ICCBBA) and developed the ISBT 128
Standard for machine readable labeling. This labeling system is an acceptable machine readable labeling standard, product description,
and bar coding system for FDA Center for Biologics Evaluation and Research under 21 CFR 606.12(c) 13. American CryoStem conforms
to this standard in its Mount Laurel facility and all cellular and tissue products produced at the facility carry our W3750 ICCBBA
facility identifier allowing any hospital, clinic, laboratory and regulator worldwide to identify the origin and obtain additional
information of any sample produced at an American CryoStem facility. The Company will promote this standard in all laboratories
that license or utilize our technology.
ATGRAFT™
Adipose Tissue Storage Service – A clinical fat storage solution allowing physicians to provide their patients
with multiple tissue/stem cell storage options. The ATGRAFT™ service, through one liposuction procedure
allows individuals the benefit of multiple cosmetic or regenerative procedures by using their own stored adipose tissue as a natural
biocompatible filler or cellular therapy application without the trauma of further liposuctions. ATGRAFT™
procedures may include breast reconstruction, layered augmentation, buttocks enhancement or volume corrections of the hands, feet,
face and neck areas that experience significant adipose tissue (fat) volume reduction as we age. ATGRAFT™
is processed and stored utilizing our standards so that any stored fat tissue sample may be retrieved in the future
and re-processed to create ATCELL™, our clinical grade stem cell product for use in Regenerative Medicine
applications. The ATGRAFT™ service is included in our pending patent application U.S. Serial No. 13/646,647.
The
Company’s charges standardized fees for ATGRAFT™ tissue processing and initial storage ranges from
$750 to $3,000, depending on the volume of tissue processed. The annual storage fee is $200 for up to 100ml of tissue. Storage
of tissue over 100ml is billed an additional $1 per 1ml annually. These fees may be paid by the collecting/treating physician
or the consumer. The Company earns additional fees ranging from $100 to $500 plus shipping costs, paid by the physician upon retrieval,
for the thawing, packaging and shipment of the stored samples to the physician for immediate use upon receipt. Additionally, physicians
may request that any stored package of ATGRAFT™ of 25ml or greater be reprocessed utilizing the Company’s
ATCELL™ and Autokine-CM™ processing. The Company charges fees of $1,500 for the
reprocessing of a 25ml stored ATGRAFT™ sample and may charge additional fee’s if additional expansion
of the newly created ATCELL™ sample is also requested.
ATGRAFT™
Processing, Storage and Retrieval fees are determined by the storage configuration as follows:
| · | Small
Sample package – for storages of 100ml of adipose tissue or less. |
| · | Medium
Sample package – for storage of 100ml to 300ml of adipose tissue. |
| · | Large
Storage package – for storage of over 300ml of adipose tissue. |
| · | Custom
Package – storage configuration for pre planned procedures. |
The
Company believes, the ATGRAFT™ service may create patient retention, and significant revenue opportunities
for the participating physician to promote additional procedures and generate additional tissue transfer fees from adipose tissue
collected during liposuction procedures. These additional fees can be generated with significantly lower physician costs by eliminating
the overhead associated with performing a liposuction for each scheduled fat transfer or therapy procedure. Physician cost savings
may include: materials, supplies, equipment, and the expenses of utilizing a surgical center, hospital operating room or an in-office
aseptic procedure room. The ATGRAFT™ service is designed to operate under the minimally manipulated regulations
contained in both 21 CFR 1271.10 and PHS 361.
ATCELL™
Adipose Derived Stem Cells (ADSCs) – Clinically processed and characterized adipose derived stem cells (ADSCs)
created using the Company’s proprietary Standard Operating Procedures (SOPs) and patented cell culture media. ATCELL™
is the Company’s trademarked name for its ADSC and differentiated cell products and processing methodology.
The Company can create multiple master and differentiated cell lines and labels them according to their characterization. (i.e.
ATCELL™ (adipose derived stem cells) ATCELL-SVF™ (stromal vascular fraction),
ATCELL – CH™ (differentiated chondrocytes), etc. Cell lines are custom created for patients
desiring to store their cells for their own use in future Regenerative Medicine procedures. The Company charges its customers
fees ranging from $1,500 to $10,000 to process a previously stored ATGRAFT™ sample or a minimum
of $2,500 for newly collected client tissue samples to be processed to Stromal Vascular Fraction (SVF). Customer samples submitted
for processing must utilize the CELLECT® collection system to conform to our internal SOPs.
The
Company believes it will earn additional fees based upon the proposed storage configuration of the final ATCELL™
sample and for additional culturing in the ACSelerate™ cell culture and differentiation
media. We believe cell culturing and differentiation can be performed upon receipt of the raw tissue sample or at any time on
a previously processed and cryopreserved ATGRAFT™ or ATCELL™ sample.
We believe ATCELL™ is ideally suited for expansion and differentiation into additional cell types
utilizing the ACSelerate™ MAX (fetal bovine serum (FBS) free high yield media),SFM (standard serum
free medium), LSM (low 0.05% FBS media) or differentiation media. The ATCELL™ products and services
are incorporated into our pending patent filing US Serial No. 13/646,647.
The
Company’s ATCELL™ cell lines are processed and cultured in our patented ACSelerate™
– MAX our high yield, animal product free cell culture media. All tissue, cells, and research materials that
are made available for sale to research institutions are tested for sterility, disease, lifespan, and population doubling rate
(PDL). Additionally, we believe these cells are suited for any type of cellular therapy or regenerative medicine research. Cell
morphology is confirmed by (i) flow cytometry and (ii) differentiation analysis using ACSelerate™
differentiation media. Each ATCELL™ line can be further cultured and differentiated allowing the
Company to provide genetically matched clinical grade cell types. We believe this research methodology may provide opportunities
for the Company’s ATCELL™ and ACSelerate™ products to become
the building blocks of final developed commercial applications.
The
Company intends to support its application research, development and collaborative efforts by making ATCELL™
and ATGRAFT™ samples available for research and product development purposes through
joint ventures, and university and commercial collaborations. These adipose tissue and cell line samples, we believe will be highly
sought after by private researchers and universities for use in pre-clinical trial studies and in-vitro research due to our clinical
processing methodology, donor sample data and the ability to create multiple cell types that have identical genetic profiles.
We believe the clinical processing methods, data collection and testing of our ATCELL™ and the
ability to make multiple cell types from the same donor line allows research teams to focus on application development and avoid
bench to commercialization delays.
ACSelerate™
Cell Culture Media Products – Manufactured patented cell culture media products for growing human stromal
cells (including all cells found in human skin, fat and other connective tissue). Certain ACSelerate™ cell
culture media lines are available in animal serum free, which is suitable for human clinical and therapeutic uses; and a low serum
version for application development and research purposes is also available. The patented ACSelerate™ cell
culture media line was specifically developed to address increasing industry demand for animal serum-free cell culture products
and for the acceleration of products from the laboratory to the patient.
On
August 2, 2011, the Company was issued US patent number 7,989,205 for “Cell Culture Media, Kits and Methods of Use.”
The granted claims include media variations for cellular differentiation of ADSCs into osteoblasts (bone), chondrocytes (cartilage),
adipocytes (fat), neural cells, and smooth muscles cells in both HSA medium (clinical) grade and FBS (research) grade. This patent
covers both non-GMP research grades and GMP clinical grades suitable for cell culture of adipose-derived stem cells intended for
use in humans. Additionally, in 2014 the Company filed a continuation of this granted patent with additional claims and improvements,
U.S. Serial No. 13/194,900. The Company has received notice from the USPTO of certain allowable claims within the continuation
application and is aggressively pursuing the granting of these additional claims.
We
believe the most widely used cell culture medium today for growing and differentiating stem cell cultures for in vitro diagnostics
and research contains 10% or more FBS. The use of FBS and other animal products in clinical cellular therapy application development
and manufacture raises concerns and generates debates within the scientific and regulatory community relating to potential human/animal
cross-contamination. These same concerns may also need to be addressed through additional expensive and expansive testing and
documentation with the FDA during the application and approval process for new cellular therapies. FDA concerns are evidenced
in their Guidance’s and Guidelines regarding cellular therapy involving human cells, tissues and products (HCT/Ps) published
and maintained by the FDA such as: Guidance for Industry: Source Animal, Product, Preclinical and Clinical Issues Concerning the
Use of Xenotransplantation Products in Humans, FDA Final Guidance, April 2003. It is our belief that eliminating or greatly reducing
FBS in cellular manufacturing, applications and products can eliminate or ease these scientific and regulatory concerns and may
prove to be a winning strategy for cellular therapy application developers seeking FDA approval.
Currently,
our media products are being utilized by our research partners engaged in developing novel new cellular applications and treatments.
The Company supports these efforts by also making ATCELL™ samples available for research purposes
and for internal product development through our research programs. We believe these cell lines are highly sought after by private
researchers and universities for use in pre-clinical trial studies and in-vitro research. We also believe that the Company’s
ability to provide clinical grade materials for these research and development collaborators, partners and other third parties
extends the Company’s ability to become a primary source of clinical grade materials and services necessary to support approved
applications and treatments.
The
Company manufactures several versions of its ACSelerate™ cell culture media including:
| · | ACSelerate-MAX™
- our improved clinical grade, animal serum free cell culture media, is ideally suited for the rapid expansion of adipose-derived
cell samples for direct use or further culturing into other cell types; |
| · | ACSelerate-SFM™
- our general purpose clinical grade, manufactured animal serum free cell culture media, which is ideally suited for
the expansion of adipose-derived cell samples for direct use or further culturing into other cell types; |
| · | ACSelerate-LSM™
- our research grade, low FBS (0.05%) cell culture media, which is ideally suited for the rapid expansion of adipose-derived
cell samples for research and cellular application development or further culturing into other research grade cell types; |
| · | ACSelerate-CY™-
for differentiation of ATCELL™ into chondrocytes (ATCELL-CY™), which are suitable
for use in cartilage repair applications in knees and other joints for patients suffering from joint injury, osteoarthritis and
other diseases that cause degeneration of joint cartilage; |
| · | ACSelerate-OB™-
for differentiation of ATCELL™ into osteoblasts (ATCELL-OB™) for the repair of
bone injuries resulting from traumatic injury and musculoskeletal diseases; |
| · | ACSelerate-AD™
- for differentiation of ATCELL™ into adipocytes (ATCELL-AD™) for the repair
of adipose tissue defects resulting from injury or surgical procedures and is designed for those patients without an appropriate
amount of body fat for corrective tissue transfer procedures; |
| · | ACSelerate-MY™-
for differentiation of ATCELL™ into myocytes (ATCELL-MY™) for the repair of muscle
tissue defects and loss as the result of traumatic injury, surgery or systemic disease; |
| · | ACSelerate-CP™-
a clinical grade, non-DMSO (Dimethyl Sulfoxide) cellular cryopreservation media designed to conform to certain FDA and PHS 361
exemptions available for marketing our ATGRAFT™ service. |
| · | ACSelerate-
TR™ - A clinical grade sterile transportation medium designed to maintain the viability of the tissue, at
ambient temperatures for up to 100 hours during the shipment of adipose tissue to our processing facility. |
The
Company continues to optimize additional versions of ACSelerate™ media through further research and testing
to develop versions for differentiation of ATCELL™ADSCs into neural, lung and other specific cell types
that may be necessary for use in future clinical applications. Many of these applications are not currently approved by the US
Food and Drug Administration. On December 31, 2014 the Company filed a new patent application for an advanced medium formulation
titled Human Albumin Serum for Cell Culture Medium for Clinical Growth of Human Adipose Stromal Cells. (US Serial No. 62/098799)
representing the most recent results of this ongoing optimization program. On December 31, 2015, the Company converted the provisional
application to an international PCT filing (PCT/US/68350) under the title Human Serum for Cell Culture for Clinical Groth of Human
Adipose Stromal Cells.
ACS
Laboratories™: Laboratory Product Sales, Contract Manufacturing and Professional Services –
ACS Laboratories is a division of American CryoStem Corporation, responsible for the manufacturing and sale of all the Company’s
patented and patent pending cellular, cell culture, processing and testing products to professional, institutional and commercial
clients. The Company operates a separate website (acslaboratories.com) to distinguish the sale of commercial and research
products from its consumer products and services, which are marketed on its main website (americancryostem.com). ACS Laboratories
manufactures a full line of ACSelerate™ cell culture media and ATCELL™ products;
and provides these products to our collaborative partners as further discussed below.
Contract
Manufacturing, Autokine-CM® Anti-Aging, Autologous Skin Care Product Line – Under agreement
with Personal Cell Sciences (PCS), we manufacture the key ingredient Autokine-CM® (autologous adipose derived
stem cell conditioned medium) for PCS’ U-Autologous™ anti-aging topical formulation. Each product is genetically
unique to the patient and custom blended, deriving its key ingredients from the individual client’s own stem cells. The
Company provides its CELLECT® Tissue Collection service to collect the required tissue to manufacture the U-Autologous
product and processes it under the same Standard Operating Procedures that it developed for the ATGRAFT™
and ATCELL™ cell processing services utilizing ACSelerate™ cell culture media.
The Company receives collection, processing and long term storage fees and earns a royalty on all U-Autologous product sales.
The utilization of the Company’s core services in its contract manufacturing relationships provides opportunities for the
Company to promote ATGRAFT™ and ATCELL™ products.
Our
Company’s contract manufacturing services can be extended to develop custom and/or white label products and services for
both local and global cosmetic and regenerative medicine companies, physicians, wellness clinics and medical spas. The Company
intends to expand its relationships and contract manufacturing regionally through its physician networks and globally through
its International Licensing Program.
International
Licensing Program – The Company believes that globally, many jurisdictions outside the US currently permit use of cellular
therapies and regenerative medicine applications. The Company has received numerous international inquiries concerning the sale
or licensing of our SOPs, products and services in the Regenerative Medicine and Medical Tourism Markets. The Company believes
that the inquiries to date are a result of the global boom in Medical Tourism, Regenerative Medicine and the slow pace of approval
of cellular therapies and regenerative medicine applications in the US. To address the Company’s sales, marketing and branding
opportunities globally, the Company has created its international licensing program. To date we have licensed our technologies
in Hong Kong and Shenzhen, China and, Tokyo, Japan.
The
Company believes it can take advantage of the significant growth of the global cellular therapy market through its international
licensing and marketing efforts. A recently published study by Transparency Market Research predicts that the Stem Cell market
will grow at a CAGR of 24.2% upon its value of US $26.23 billion in 2013 and will reach an approximate value of US $119.52 billion
by 2019. The report, titled “Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012
- 2018”; which can be found at (http://globenewswire.com/news-release/2014/12/22/693419/10113247/en/Global-Stem-Cells-Market-to-grow-at-a-CAGR-of-24-2-to-Push-US-119-52-billion-by-2019-Transparency-Market-Research.)
Product
Development
Our
strategic approach to product development is to design, develop and launch new products and services that utilize our existing
products and services. Management believes that this approach will provide the Company with opportunities to produce near term
cash flow, strong recurring revenue streams, strong international licensing partners and complementary scientific data. We focus
on developing products, services and applications that require tissue collection and processing as the initial requirement to
produce cellular therapies and products. These products and services may include adipose tissue and stem cell sample processing
and storage as a form of personal “bio-insurance”, adipose tissue (fat) storage for cosmetic fat engraftment
procedures, and the creation and production of topical applications and ingredients used by other companies in the wound care
and cosmetic industries as well as cellular applications and bio-materials development.
We
intend to focus our efforts on expanding our product and services pipelines based upon our intellectual property portfolio, collaborative
development relationships, product sales and distribution, and international licensing and partnering opportunities. Our current
activities include supporting our university and industry collaborations by providing our products and services with the expectation
that our products and services become the basis for new adipose tissue and stem cell based Regenerative Medicine and cellular
therapy applications. We believe this strategy allows our proposed research partners and their application development to begin
with clinically harvested and processed adipose tissue and ADSCs (ATCELL™), which may be a significant
step toward accelerating the development and approval of new treatments.
Collaboration
/ Partnering Opportunities / Acquisitions
BioLife
Customer and Physician Acquisition
In
February 2015 the Company entered into a binding asset purchase agreement with BioLife Cell Bank Dallas, LLC and BioLife Cell
Bank Management, LLC (collectively “BioLife”), to purchase all of BioLife’s current adipose tissue, stem cell
storage clients samples, and physician network. The transaction was concluded in March of 2015. Transfer of the adipose tissue
samples was completed on April 24, 2015 and the Company undertook a complete physical inventory of the transferred samples. The
Company initiated annual storage fee billing to the acquired storage clients in June of 2015. Management believes that, with the
acquisition of BioLife, the Company became one of the largest commercial adipose storage facility in the United States.
Additionally
the Company acquired the physician customer list of approximately 60 cosmetic and plastic surgeons, and began marketing its services
to all previous physician users of the BioLife services.
Protein
Genomics and Formation of Autogenesis Corporation
In
2012, American CryoStem entered into a Memorandum of Understanding (MOU) outlining our initial collaborative efforts with Protein
Genomics, Inc. (PGEN) to test and develop new products by combining certain components of our respective intellectual property
and patented products. We have provided PGEN and its research partner, Development Engineering Sciences (DES), with Adipose Derived
Stem Cells (ATCELL™) and our patented cell culture mediums (ACSelerate™) for testing
with PGEN’s patented products designed for the wound healing market. Research and development has been ongoing since late
2012 and notable progress has been achieved.
As
a result of the success realized in the early stage of this research collaboration, in fiscal 2013 we entered into a formal joint
venture with Protein Genomics through the incorporation of Autogenesis, Corp. as required by the 2012 MOU. Each company (CRYO
and PGen) initially has an equal ownership interest. All products capable of being commercialized, as well as any new intellectual
property, resulting from the ongoing scientific collaboration will be wholly-owned by Autogenesis. This is representative of how
we believe additional research collaborations utilizing our Company’s technology may evolve in the future.
During
2013 and 2014, the collaborative efforts resulted in successful initial “proof of concept” combining PGEN’s
unique biomaterial and the Company’s ATCELL™ and ACSelerate™ products. Management
believes the publication of the preliminary results showed successful healing of full depth wounds on the backs of immune deficient
mice.
Our
collaborative research has established that membrane scaffolds fabricated from human proteins can be cultivated with ATCELL™
cells causing the scaffolds to be rapidly and completely covered by the cells. The cells then secrete their own extracellular
matrix, creating a structure with layers of matrix, cells and scaffold. This living structure, when introduced into a mouse wound
model, localizes the stem cells in the wound, protects the cells within the wound environment, promotes cell growth and causes
a statistically significant increase in the rate of wound closure and healing compared to the standard of care. Further
evaluation will measure the performance of these scaffolds in accelerating the rate of wound closure, healed scar thickness,
growth of new blood vessels and production of key wound healing factors. Our objective is to show that these constructs can stimulate
the growth of new tissue and promote wound closure and healing.
INTEGRA
LifeSciences:
On
June 4, 2015, the Company and Autogenesis, Corp. entered into Non-Disclosure and Material Transfer Agreements with Integra LifeSciences,
under which the parties are exploring certain combinations of American CryoStem’s, ATCELL™ stem
cells, its licensed biomaterials and Integra products and other biomaterials for the development of new products and services.
Integra LifeSciences, a NYSE traded (INT) New Jersey based company, is a world leader in medical technology and wound healing. Integra
offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue
technologies. (http://www.integralife.com/)
Under
the terms of the Agreement the Company will supply biomaterials to Integra and utilize its AGRFAFT™,
CELLECT®, ATCELL™ and ACSelerate™ products for the development
of new devices and biologic products for use with the co-developed biomaterials. To date the Company has delivered biomaterials
to Integra for use in the development of the new biomaterials and initiated the processing and testing of porcine (pig) adipose
tissue for use in the initial animal studies. The Company is currently working with Integra to schedule additional work necessary
to advance the product development in 2016 which include additional porcine tissue processing, and combining our ATCELL™
and ACSelerate™ products with the new materials.
Rutgers
University
In
May of 2012, American CryoStem entered into Material Transfer Agreements with three research scientists at Rutgers University
allowing them to utilize the Company’s autologous Adipose-Derived Stem Cells (ATCELL™) and patented, serum free, GMP
grade cell culture and differentiation mediums (ACSelerate™) for evaluation with the anticipation to implement additional
agreements to research, develop and commercialize innovative new cellular therapies targeting incurable diseases, neurological
disorders and the $5 billion global wound care market.
During
the last quarter of 2015 the Company undertook a review of the collaborative efforts between the Company and Dr. Lee pending the
expiration of the agreements in November of 2015. Management believes that potential commercialization of the licensed technologies
would require a number of years of additional study and experimentation and requires substantial investment by the Company. In
November of 2015 the Collaboration and Research Agreement and the Licensing Agreement were terminated. The Company continues to
discuss alternative arrangements with Dr. Lee and the Rutgers Office of Technology Transfer for the continuing provision of our
ATCELL™ and ATGRAFT™ products to Dr. Lee to support his continuing research.
Cells
on Ice:
In
August of 2015 the company entered into an Agreement with Cells On Ice, Inc. (COI) located in Los Angeles, California to process
adipose tissue and adipose derived cellular samples for future use in Regenerative Medicine. COI is a network of physicians interested
in the development and use of adipose tissue and adipose derived cellular samples in regenerative therapies and cellular medicine.
The Company has agreed to distribute its CELLECT® collection boxes and provide its ATGRAFT™
and ATCELL™ processing services under the COI brand for the collection, processing and storage of tissue
samples at its NJ facility. Under the agreement, COI will pay the Company for the processing and storage of each sample generated
by COI network physicians. COI plans to seek regulatory approval for use of the stored samples in clinical studies and trials
utilizing adipose tissue processed into Stromal Vascular Fraction (SVF) and ultimately expanded adipose derived mesenchymal adult
stem cells. The Company is incorporating its existing Institutional Review Board (IRB) approved protocols into COI’s studies
and may provide processing and other data to COI in support of their ongoing efforts to develop and obtain regulatory approval
of its cellular therapies.
Additional
Collaborations
The
Company is in the early stages of developing collaborations with additional industry and university partners. These developing
relationships in their earliest stages are covered by Confidential Disclosure Agreements and those that are more advanced also
include Material Transfer Agreements under which the Company supplies either ATCELL™ or ACSelerate™
medium products for evaluation, testing, and the development of new cellular therapy applications.
To
Date the Company has advanced to a Material Transfer Agreement with the University of Miami, University of Washington, UHV Technologies,
and STEMCell Technologies and has provided both ATCELL™ and ACSelerate™ products to these entities
under Agreement. No assurance can be given that these relationships will progress to full collaborative agreements or ultimately
result in new technology for future commercialization. As of September 30, 2015 these relationships have yet to result in a material
agreement.
Additionally
in August of 2015 the Company entered into a Confidential Disclosure Agreement and a Material Transfer Agreement with Dr. Sazlay,
a research scientist currently investigating unique cancer treatments at the University of Wurzburg in Germany and the University
of California in San Diego. Following execution of the Agreement, the Company delivered a number of ATCELL-SVF™,
ATCELL™ and ACSelerate™ samples to Dr. Sazlay for testing and determination of
usefulness of our products for development of his novel treatments. Dr. Sazlay has reported positive results of this initial work
and the Company and Dr. Sazlay are currently negotiating additional collaborative agreements for further development of the treatments.
Institutional
Review Board Approval of Protocols
In
an effort to make it easier for other physicians and researchers to study the safety of SVF and ADSCs, in 2013 we sought approval
from the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS) of our protocols for the processing
of SVF and culturing of mesenchymal stem cells from autologous adipose tissue. The two protocols, titled: Autologous Adipose
Tissue-Derived Stromal Vascular Fraction (SVF) Containing Adult Stem Cells with Isolation of SVF, and Culturing
of Adipose Derived Stem Cells (ADSCs) For Use in Institutional Review Board Studies, (the “IRB Studies”) provide
appropriate processing, storage and testing methods necessary to move the clinical investigative process towards uniform treatments.
The collection of processing and outcome data from IRB approved protocols is required by prevailing FDA regulations and guidance
for approval of regenerative cellular therapies, including potency (cell count), contamination testing and cell viability.
The
ICSS IRB thoroughly evaluated every step of our standardized processing protocols, which serve to isolate the SVF or ADSCs from
a patient’s adipose tissue. The objective of the IRB is to assess these protocols to ensure the highest patient safety possible
and to minimize the risks for those participating in innovative research and investigational studies. On June 30, 2013, the ICSS
IRB approved the protocols until June 30, 2014. Additionally, the Company obtained approval for a new study, entitled “Comparative
Viability Assessment of Human Adipose Tissue before and After Cryopreservation (ICSS -2013-010), the Study was approved
on November 22, 2013 and is valid until November 22, 2014
In
June of 2014 the Company submitted its IRB Studies to the Institutional Review Board of the Institute of Regenerative Cellular
Medicine (the “IRCM”) and on July 23, 2014 the ICEM IRB approved the following studies:
| · | Isolation
of SVF: Autologous Adipose Derived Stromal Vascular Fraction Containing Adult Stem Cells (IRCM 2014-024) until July 23,
2015 |
| · | Comparative
Viability Assessment of Humean Adipose Tissue Before and After Cryopreservation (IRCM 2014-025) until July 23, 2015 |
| · | Isolation
of SCF and Culturing Adipose Derived Stem Cells for Use in Investigational Review Board Studies (IRCM 2014-023) until
July 23, 2015 |
The
IRCM approved studies require annual renewal; the Company renewed the studies in July of 2015.
The
Company is currently making its processing services available to physicians and clinical researchers utilizing the IRB-approved
protocols for inclusion in their studies. By adopting these standardized and repeatable protocols utilizing our laboratory services,
researchers are able to focus their resources on application development rather than creating, validating and managing a clinical
laboratory for processing tissue and cellular samples. These studies above do not currently involve actual human clinical trials,
but affords the IRB the opportunity to endorse our repeatable, standardized and validated processing methodologies for the isolation
of SVF and for tissue culture expansion of ADSCs obtained from SVF as the basis for future human clinical study.
In
2014, the Company created and is the Sponsor of a new IRB study with The DaVinci Center, Dr. Louis Cona, Principal Investigator,
in George Town, Grand Cayman Island entitled Impact and Safety of Cultured Expanded Autologous, Adipose-Derived
Stem Cells deployed via Intravenous Injection for the Treatment of Multiple Sclerosis Protocol: CRYO-MS-ADSC-006. On July
23, 2014 the study was approved for 100 patients. On November 1, 2014 the first patient was treated at the Da Vinci
Center utilizing the approved protocol. The IRB filing can be found on www.clinicaltrials.gov, (ClinicalTrials.gov Identifier
NCT02326935). The Company renewed the IRB studies with The Institute of Regenerative Cellular Medicine in August of 2015 for another
one year period.
Management
intends to pursue additional collaborative and partnering opportunities as a strategic method to enhance awareness of and expand
the distribution of our patented products, services, technologies and expertise in the IRB-approved clinical processing of adult
adipose tissue and ADSCs for autologous (self) use. We believe that as the pace of clinical trials and cellular therapy results
reporting increase and scientific and peer reviewed papers are published, new opportunities to market our existing products, services
and Intellectual Property portfolio may also emerge.
Moreover,
we further believe that the combination of our validated cellular processing capabilities and patented products give us an economical
platform to develop and produce cellular therapy applications for injection or intravenous therapy, topical applications, burn
and wound healing, joint repair, disease treatments and cosmeticeuticals. The clinical methods and products we have developed
are designed to permit a variety of treatments for any patient with their own genetically matched raw materials utilizing our
ATCELL™ and ATGRAFT™ products prepared with our patented line of ACSelerate™
cell culture mediums. We believe that autologous cellular therapies have shown promising results for safety and efficacy
in a variety of applications in published early stage clinical trial results and application studies.
Regulatory
Information
The
Company believes that its processing methodologies and the testing laboratory facilities are designed to be in compliance with
all current regulations as defined by the United States Public Health Service Act (“PHS” or the “PHS Act”)
and the Food and Drug Administration (FDA) regulations as they relate to the operation of a tissue processing and storage facility.
The
Company’s Mount Laurel facility is registered with the FDA (FEI 3008307548) as a processing and storage facility for Human
Cells, Tissues and Cellular and Tissue Based Products (HCT/Ps) since 2010. In 2013, we registered the facility with the State
of New York (CP169TP136) and the State of California (CNC80948) the only states in the U.S. requiring registration. These state
registrations required the submission of our operating procedures for review by the respective State Health Departments, and annual
updates to maintain the registrations are required. In addition, we have discussed our operations with the State of New Jersey
Health Department and Department of Environmental Protection (DEP) to ascertain any special regulations to which we may be subject.
Based upon these discussions, and our use of a registered medical waste disposal company, we do not at this time have any special
registrations or regulations for compliance with the State of New Jersey. Our New Jersey Medical Waste Generator registration
number is 0364539.
The
Company is also subject to complying with a significant body of FDA and PHS regulation; the regulations governing our business
are mainly contained within 21 CFR 1271.10, 800, 600, 200, 210 and 211. The forgoing regulations govern all aspects of the Company’s
Standard Operating Procedures (SOPs), which we periodically review with our FDA advisors, Laboratory Director and Medical Laboratory
Director.
Our
SOPs are the key to properly operating our clinical tissue processing facility. To ensure delivery of the highest quality services,
we incorporate these SOPs, which are designed to provide a basis for accreditation by the American Association of Blood Banks
(AABB), the American Association of Tissue Banks (AATB) and the Foundation for the Accreditation of Cellular Therapy (FACT-JACIE).
We have consistently endeavored to ensure that our processes, methodologies and procedures remain among the highest standards
in the global tissue collection, processing and storage market. To this end, we have equipped ourselves with state-of-the-art
quality processing and testing equipment, which we believe helps to ensure that every sample collected and processed is sterile
(free from adventitious agents), viable and capable of significant cellular growth and expansion.
Quality
Management
The
Company’s quality management program attempts to ensure that during processing and testing of each adipose tissue or SVF
sample, the appropriate quality management tests and processing methodologies are performed and the data is collected, recorded
and reviewed by the laboratory management team.
Chain
of Custody Control
Central
to the individual sample testing is an unbroken chain of custody and tracking. Sample tracking begins with the creation of each
collection box. All samples, processing, quality management, batch, and storage documents and records, are coded with this unique
number. All records and testing samples are cross referenced and verified as required by the standard operating procedures.
Testing
Design and Standard Operating Procedures (SOPs)
Testing
methods are standardized and operate under a complete set of validated SOPs and Quality Management (QM) processes. All SOPs are
designed to be in compliance with the US Food and Drug Administration’s regulations and guidance for aseptic processing.
Strict QM is enforced to avoid and/or record any process deviations.
Intellectual
Property
From
the Company’s formation, our strategy has been to invest time and capital in intellectual property protection. This strategy
is intended to strengthen our Company’s foundation in any defensive or offensive legal challenge. In addition, we are developing
our IP portfolio to ensure and enhance our business flexibility and allow us to gain favorable terms in potential future collaborative
partnerships with third parties. Our intellectual property portfolio currently includes one issued U.S. patent (No. 7989205, Cell
Culture Media Kits and Methods of Use); and five pending patent applications which are detailed in the following chart:
PATENT
TITLE |
USE
OF PATENT |
APPLICATION
# |
A
Business Method for “Collection, Cryogenic Storage and Distribution of a Biological Sample Material” |
Company
Core Tissue Collection Processing and Storage Methodology |
U.S.
Serial No. 13/702,304 filed June 6, 2011, and claiming a priority date of June 7, 2010 from provisional application 61/352,217 |
Systems
and Methods for “The Digestion of Adipose Tissue Samples Obtained From a Client for Cryopreservation” |
Adipose
Tissue Digestion Laboratory Processing Methods |
U.S.
Serial No. 13/646,647 filed October 5, 2012, and claiming a priority date of October 6, 2011 from provisional application
61/544,103 |
Compositions
and Methods for “Collecting, Washing, Cyroprocessing, Recovering and Return of Lipoaspirate to Physicians for Autologous
Adipose Transfer Procedures” |
Company
Adipose Tissue Storage Platform for Cosmetic Procedures |
PCT/US13/44621
Filed June 6, 2013 and claiming a priority date of June 7, 2012 |
Stem
Cell-Based Therapeutic Devices and Methods |
Combining
ADRCs with Biomaterials for healing and tissue growth |
U.
S. Serial No. 14/196,616 filed March 4, 2014 and claiming a priority date from provisional
application 61/773,112 filed March 5, 2013 |
Autologous
Serum for Transport of Isolated Stromal Vascular Fraction or Adipose Derived Stem Cells |
Utilization
of Autologous Blood Components for the Transport of Adipose Derived Cells to a Patient |
U.S.
Serial No. 14,250,338 and claiming a priority date from provisional application 61/810,970
filed
April 11, 2013 |
Cell
Culture Media, Kits, and Methods of Use |
Continuation
of U.S. Serial No. 11/542,863, includes Optimized and improvements to Media Formulations |
U.S.
Serial No. 13/194,900 |
Human
Serum for Cell Culture Medium for Clinical Growth of Human Adipose Stromal Cells |
International
PCT filing of US Provisional Application Serial Number 62/098799 Filed December 31, 2014 |
PCT/US/68350
Filed December 31, 2015 |
Additionally,
the Company has in-licensed IP with the following collaborations and joint ventures;
PATENT
TITLE |
USE
OF PATENT |
APPLICATION
# |
Cosmetic
compositions including tropoelastin isomorphs |
Protein
Genomics and American CryoStem (Autogenesis) collaboration |
USPTO
#5,726,040 |
Cosmetic
compositions |
Protein
Genomics and American CryoStem (Autogenesis) collaboration |
USPTO
#6,451,326 |
Recombinant
hair treatment compositions |
Protein
Genomics and American CryoStem (Autogenesis) collaboration |
USPTO
#6,572,845 |
Wound
healing compositions and methods using tropoelastin and lysyl oxidase |
Protein
Genomics and American CryoStem (Autogenesis) collaboration |
USPTO:
#6,808,707 |
Business
methods, processes and systems for collection, cryogenic storage and distribution of cosmetic formulations from an obtained
stem cell based biological |
Personal
Cell Sciences and American CryoStem collaboration |
USPTO
application #61/588,841 |
Trademarks
In
addition to patents, the Company has registered the following trademarks with the U.S. Patent and Trademark Office: American
CryoStem®, CELLECT® and ATGRAFT™. We plan to obtain additional registered
trademarks for our future products, slogans and themes to be used in our marketing initiatives, including, for example, ACSelerate-SFM™,
ACSelerate- LSM™ and ATCELL™.
The
Company has also secured a number of online domain names relevant to its business, including www.americancryostem.com and www.acslaboratories.com.
Market
Size and Opportunities
By
leveraging and capitalizing on our proprietary Adipose Tissue Processing Platform, our Company is working to address multiple
high growth, multi-billion dollar market opportunities, including those prevailing within the Regenerative Medicine, Cosmeceuticals,
Medical Tourism and Cell Culture Media markets. The Company regularly reviews independent market research to gauge the market
size of its intended domestic and international markets and to identify additional areas within these markets where the Company’s
cell culture medium, laboratory products, and tissue and cellular processing services, can be marketed, sold and/or licensed.
Global
Stem Cells Market
A
recently released report from Transparency Market Research (TMR) forecasts that the global stem cells market will grow
at a remarkable CAGR of 24.2% from 2012 to 2018. According to TMR, a market intelligence firm, the global stem cells market, which
in 2013 stood at US$26.23 bn, is anticipated to reach US$119.52 bn by the end of the forecast period. The report, titled ’Stem
Cells Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018’, http://www.transparencymarketresearch.com/pressrelease/stem-cells-market.htm
Another
report by Transparency Market Research titled “Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends
and Forecast, 2012 - 2018” states “The Global Stem Cells Market to grow at a CAGR of 24.2%, to Push US$119.52
billion by 2019. The report analyzes the highly fragmented stem cells market by the type of stem cells, processes in the
stem cell market, applications of stem cells, and geography. Regenerative medicine is by far the dominant application of stem
cells, including uses in neurology, cardiology, and oncology. According to process, the market is divided into the stem cell acquisition,
stem cell production, stem cell cryopreservation, and stem cell expansion segments. Due to the expected increase in demand, stem
cell acquisition will retain its position as the major segment of the stem cell market. Geographically, North America and Europe
will remain well ahead of the competition.”
(http://globenewswire.com/news-release/2014/12/22/693419/10113247/en/Global-Stem-Cells-Market-to-grow-at-a-CAGR-of-
24-2-to-Push-US-119-52-billion-by-2019-Transparency-Market-Research.html#sthash.4vzqG1wc.dpuf)
Regenerative
Medicine Market
According
to a leading research firm focused on the biotechnology, healthcare and life sciences industries, TriMark Publications categorizes
the Regenerative Medicine market into three main categories:
| · | Biomolecules
(scaffolds, growth factors and stem cell therapy). |
TriMark
Publications.com cites in its “Regenerative Medicine Markets” report (March 2013) that the Regenerative Medicine market
continues to witness significant advances in clinical efficacy, regulatory approval and product commercialization of cell based
therapies which will catapult to over $35 billion by 2019. Affirmative results produced from the application of adult stem cells
have resulted in greater government and private sector investment in research and development of new cell therapies. Investment
made into the regenerative medicine market include firms that harvest, process, purify, expand, cryopreserve, store or administer
stem cells”1 In a study from Market Research Reports, released “Global Regenerative Medicine Market (Technology,
Applications, Geography) – Industry Analysis, Trends, Opportunities and Forecast, 2013-2020.” In it, the market analysis
firm found the global regenerative medicine market will be worth some $67.6 billion by 2020 – a stark and notable
increase from the $16.4 billion valuation it received in 2013. Between 2014 and 2020, the report expects the regenerative medicine
market to grow at a compounded annual growth rate of 23.2 percent.
According
to Allied Market Research, on the basis of geography, this market can be classified into
North America, Europe, Asia-Pacific and LAMEA. Currently, North America dominates the global market due to heavy investment in
development of regenerative products as well as more number of commercialized products. However, the growing focus on research
and development in Japan and South Korea makes Asia-Pacific the fastest growing region at a CAGR of 30.9% during 2014-2020.
Medical
Tourism, Global Wellness Tourism
As
stated by the Global Wellness Institute; adding up all expenditures made by international/inbound and domestic, primary and secondary
wellness tourists, we estimate the wellness tourism industry to be $494 billion in 2013, a 12.7% increase over 2012. Wellness
tourism accounts for 14.6% of all tourism expenditures and is growing much faster than the 7.3% growth rate for overall tourism
expenditures from 2012-2013.The $494 billion in wellness tourism expenditures represent 586.5 million wellness trips taken in
2013, across 211 countries. Wellness tourism accounts for about 6.2% of all domestic and international tourism trips taken in
2013.
http://www.globalwellnesssummit.com/images/stories/gsws2014/pdf/GWI_Global_Spa_and_Wellness_Economy_Monitor_Full_Report_Final.pdf
Cell
Culture Market
The
Company believes the reproducibility of scientific studies has become a substantial issue in life science research from drug discovery
and development through clinical trials as researchers throughout the world continue to use different protocols for processes
associated with sample preparation, cryopreservation and cold chain management. We believe the scientific community is becoming
more aware of factors that affect sample integrity and experiment variability. By standardizing handling, storage, and transportation
protocols we believe we can substantially improve the quality and reproducibility of preclinical and clinical data which we believe
will help to accelerate the transition from lab research to drug development and market launch.
1http://www.trimarkpublications.com/regenerative-medicine-markets/
According
to MarketsandMarkets, the global cell culture market was valued at an estimated $14,772 million in 2013. This market is expected
to grow at a CAGR of 10.71% between 2013 and 2018, to reach $24,574 million in 2018. The cell culture media, sera, and reagents
market consists of six segments, namely, contamination detection kits, cryoprotective agents, lab reagents, media, serum, and
other reagents. Of these, the serum product segment had the largest share of the cell culture media, sera, and reagents market
in 2013, whereas the media product segment is expected to grow at the highest CAGR between 2013 and 2018.
Cosmeceutical
Market
Many
industry experts agree that Cosmeceuticals has become one of the the fastest growing segments of the Cosmetics and Personal Care
industry. Cosmeceutical products have a big emphasis on scientifically advanced formulations and often contain active ingredients
that can also be found in pharmaceutical products. This continued emergence of increasingly sophisticated active ingredients is
said to be the main driving force behind the growth of this segment, which is rapidly evolving into significant category of the
personal care industry.
In
a report titled Global Cosmeceuticals Market Outlook 2016, published February 2013, RNCOS reports that the worldwide market
is estimated to be valued at $30.5 billion and is likely to grow at a consistent CAGR of 7.7% during the period 2012 through 2016.2 In a separate report, Transparency Market Research, a U.S. - based market intelligence
firm states that the global facial care market is expected to report an approximate value of $39.75 billion by 2019. The report,
titled ’Facial Care Market (By Product Type - Skin Whitening/ Lightening and Anti-Ageing, Facial Creams, Face Wash,
Cleansing Wipes, Serums and Masks and Others (fade creams, pore strips and toners)- Asia-Pacific Industry Analysis, Size, Share,
Growth, Trends and Forecast 2013 – 2019. http://globenewswire.com/news-release/2014/10/17/674123/10103135/en/Global-Facial-Care-Market-to-be-Worth-39-75-Billion-by-the-year-2019-Transparency-Market-Research.html
Marketing
and Distribution
The
key objective of our marketing strategy is to position American CryoStem in the market as the “Gold Standard” for
adipose tissue collection, cell processing and cryogenic storage, therapeutic applications, and research/commercial uses of adipose
tissue within the current regulatory framework. The combination of a traditional sales approach supported by continuous internal
and external marketing programs, are closely coordinated with the expansion of our laboratory processing capabilities. Our initial
marketing efforts intend to disseminate current and future uses of adipose tissue and adult stem cells which support our business
model, products and services. In 2015, we intend to continue to employ both print advertising and social media sales campaigns.
In addition, we plan to continue to utilize key leaders, and early adopters in the medical community as a marketing resource to
enhance awareness of our proprietary, patented products and services and to increase the number of surgeons who join our network,
university and private collaboration and consumers who use our products and services.
We
plan to continue direct marketing programs focused on reaching plastic and cosmetic surgeons to join the initial group of providers
that began to offer our services to their patients in 2014. This marketing initiative has been implemented using a traditional
sales approach common to the pharmaceutical and biotechnology industries. This fundamental sales approach at the core of our marketing
activities is being strategically and tactically expanded using a combination of in-house sales personnel and outside independent
channels.
Our
plan, capital permitting, provides for a comprehensive integrated marketing approach using various traditional and new media,
such as the Internet, social media/blogging, video, print, TV, radio and trade shows to reach targeted potential consumers and
promote awareness of our Company and our branded products and services. The essence of this targeted strategy is to reach the
end-users as quickly as possible and to accelerate the adoption curve of our products and services. We also plan to utilize outside
marketing resources and trade groups to increase the number of surgeons willing to offer our products and services to their patients.
Development
of Regional U.S. Markets
Cells
on Ice
In
August of 2015 the company entered into an Agreement with Cells On Ice, Inc. (COI) located in Los Angeles, California to process
adipose tissue and adipose derived cellular samples for future use in Regenerative Medicine. COI is a network of physicians interested
in the development and use of adipose tissue and adipose derived cellular samples in regenerative therapies and cellular medicine.
The Company has agreed to distribute its CELLECT® collection boxes and provide its ATGRAFT™
and ATCELL™ processing services under the COI brand for the collection, processing and storage of tissue
samples at its NJ facility. Under the agreement, COI will pay the Company for the processing and storage of each sample generated
by COI network physicians. COI plans to seek regulatory approval for use of the stored samples in clinical studies and trials
utilizing adipose tissue processed into Stromal Vascular Fraction (SVF) and ultimately expanded adipose derived mesenchymal adult
stem cells. The Company is incorporating its existing Institutional Review Board (IRB) approved protocols into COI’s studies
and providing processing and other data to COI in support of their ongoing efforts to develop and obtain regulatory approval of
its cellular therapies.
2http://www.researchandmarkets.com/research/mbmvbh/global
Physician
Network
The
Company continues to develop regional relationships to leverage its new products and services through existing cosmetic surgery
and regenerative medicine practices. The Company continues to develop and expand its network of physicians seeking to adopt its
products and services, initially focusing on surgeons performing liposuction, tissue transfer and regenerative procedures involving
the use of adipose tissue. The Company intends to continue expanding its efforts to medical professionals interested in Regenerative
Medicine applications utilizing ASDCs and establish itself as a primary source of collection, processing, and preparation of cellular
therapies as they are developed and approved for patient use by the FDA.
Development
of International Markets
International
Licensing Program – Globally, many jurisdictions outside the US permit the use of adipose tissue, cellular therapies
and regenerative medicine applications. The Company has received numerous inquiries concerning the sale or licensing of our products
and services in these jurisdictions. The Company believes that the inquiries to date are a result of the global boom in Medical
Tourism and the slow pace of approval of cellular therapies and regenerative medicine applications in the US. To address these
inquiries and to expand the Company’s sales, marketing and branding opportunities the Company has designed and is offering
an International Licensing Program.
The
program is designed to permit the licensing of the company’s products and services to organizations that meet the Company’s
financial and technical criteria. The licensing program allows for a variety of business relationship including franchising, partnering
and joint venturing. Marketing efforts to date have been to clinics, physician and hospitals in foreign jurisdictions capable
of rapidly building or committing the appropriate facilities and personnel to create the required laboratory facilities to operate
the CELLECT®, ATGRAFT™ and ATCELL™ services in
their local market. Strategically, the Company’s international licensees will maintain the branding of the Company’s
services along the lines of the “Intel Inside” branding program.
Qualified
Licensees can quickly take advantage of the rapidly expanding opportunity to collect, process, store and culture individual stem
cell samples for their clients with the comfort and confidence that they are providing services that have been developed to US
FDA standards. Core to the relationship is the developed proprietary and patent pending processing and laboratory operational
methodologies contained in our Standard Operating Procedures, Training, and Continuous Quality Management, Testing Program, and
Laboratory Operations manuals.
Licensing
programs may be initiated through a letter of intent (LOI) agreement between the Company and the prospective licensee. This LOI
agreement is designed for due diligence and facility qualifications purposes. The Company may receive an initial fee under the
agreement which is credited toward future royalty payments. Following evaluation of the prospective licensee the Compay will enter
into a final Agreement which outlines all upfront fees, minimum royalties and consumable purchase obligations of the Licensee.
Significant
to our international development activities is the global expansion of the American CryoStem branded services and patented products,
as well as the expansion of the Company’s services, technology and products as the core platform to implement cellular therapies
and regenerative medicine.
Health
Information Technology Company, LTD (Hong Kong)
On
June 30, 2014 the Company granted Health Information Technology Company, LTD (“HIT”) exclusive rights to utilize the
Company’s Standard Operating Procedures (SOP’s) to market the Company’s ATGRAFT™ tissue storage
service for Hong Kong. The Agreement calls for upfront fees, royalties and the purchase by HIT of certain consumables manufactured
by the Company. The Company and HIT have reached further agreement to extend their relationship on a non exclusive basis to include
HIT’s cord blood laboratory located in Shenzhen, Guangdong Province, one of China’s most successful Special Economic
Zones. The HIT agreement includes, initial upfront fees and royalty payments for predetermined gross revenue volumes. HIT will
also purchase CRYO ACSelerate™ storage media, CELLECT® collection and transportation kit as well
as other American CryoStem products necessary for clinical adipose tissue processing and storage at the Shenzhen cord blood collection
facility. The final master licensing agreement is for a period of 5 years with renewal options and was executed between the parties
on September 24, 2014.
CellSource.
Tokyo, Japan
In
the second quarter of 2015 the Company entered into negotiations with CellSource, LLC in Tokyo, Japan for the licensing of its
ATGRAFT™ products and services and on June 2, 2015 the Company and Cell Source entered into an initial term sheet
Licensing the ATGRAFT™ technology to Cell Source for Japan. The Agreement further calls for Cell Source to purchase
our CELLECT® collection boxes and ACSelerate™ Cryopreservation Medium and provides Cell
Source with a limited Right of First Refusal for licensing additional technologies for the Japanese markets. According to Allied
Market Research, World Regenerative Medicines Market Currently, North America dominates
the global Regenerative Medicine market due to heavy investment in development of regenerative products as well as more number
of commercialized products. However, the growing focus on research and development in Japan and South Korea makes Asia-Pacific
the fastest growing region at a CAGR of 30.9% during 2014-2020.
Scientific
and Medical Advisory Board 2015
To
expand our Scientific, R&D and product marketing efforts we continue to actively recruit and enlist the services of highly
qualified peer leaders through our Scientific and Medical Advisory Board to assist us in our industry speaking engagements and
education platform. This education platform is designed to focus on physicians, and industry needs and demands as they relate
to current and future treatments utilizing our adipose tissue platform and adult stem cell technologies. Additionally, certain
members of our advisory board provide assistance and input to management on the oversight of our research relationships, laboratory
development and quality management systems. As of September 30, 2015, the following are currently members of our Scientific and
Medical Advisory Board: (2016)
Dr.
Gao is a world-renowned Professor of Mechanical Engineering and Biomedical Engineering at the University of Washington in Seattle.
He has been actively engaged in cryopreservation research for more than 20 years, with specific emphasis on fundamental and applied
cryobiology, which is the investigation of mechanisms in cryo-injury and cryo-protection with respect to living biological systems
at low temperatures; with the development of optimal methods and technologies for the cryopreservation; and with the banking of
living cells and tissues for biomedical applications. Dr. Gao has published 175 research papers in prestigious scientific/biomedical
journals, with over 250 papers/abstracts in conference proceedings. He has obtained 16 patents, and authored two scientific books
and numerous chapters in 17 scientific books. He currently serves on the Editorial Board, as Editor-in-Chief, of six scientific
journals, and is the Editor of the Cryopreservation Engineering section of Biopreservation and Biobanking. His research
in cryobiology and cryopreservation has been funded by the National Institutes of Health, the American Cancer Society, the Bill
and Melinda Gates Foundation, the American Heart Association, the Whitaker Foundation, the Washington Research Foundation and
the Kentucky Science Foundation, among others. Dr. Gao graduated with B.Sc. degree from the University of Science and Technology
in China, and received a Ph.D. in Mechanical Engineering from Concordia University, Montreal, Canada.
| · | Fredric
A. Stern, MD, FACS |
Dr.
Stern is the founder and Medical Director of the Stern Center for Aesthetic Surgery in Bellevue, Washington. Following his education
at Columbia University Medical School, Dr. Stern earned his Board Certification in Ophthalmology at the University of Washington,
and underwent extensive additional training in oculofacial plastic and laser surgery. In 1987, he joined Virginia Mason Medical
Center in Seattle, serving as Director of the Oculoplastic Surgery Division for ten years. While at Virginia Mason, Dr. Stern
performed an extensive number of cosmetic laser procedures. He is honored to have been chosen as one of a select group of instructors
of the Botox Cosmetic® National Education Faculty, as well as the Radiesse™ Medical
Education Faculty. Dr. Stern is also an instructor for the Sciton™Laser. In 2011, he was voted
the Best Plastic Surgeon in Western Washington by KING 5 (NBC affiliate) TV’s viewing audience. Dr. Stern is a Fellow
of the American College of Surgeons, the American Academy of Facial Plastic and Reconstructive Surgeons, the American Academy
of Cosmetic Surgery, and the American Society of Liposuction Surgery, as well as a member of the International Society of Hair
Restoration Surgery. In addition, over the past several years, he has appeared on Northwest Afternoon, Evening Magazine,
as well as KOMO, KIRO and Q13 news, discussing and demonstrating the latest techniques in facial and eyelid
laser cosmetic surgery, Botox® and laser-assisted liposuction. He is also an accomplished winemaker &
published novelist. Dr. Stern’s latest novel is a medical thriller titled, The Sigma Project.
Dr.
Bircoll was the first plastic surgeon to perform liposuction in North America. He pioneered that operation and saw it from its
early beginnings to become what is now the most frequently performed cosmetic procedure worldwide.Dr. Bircoll is also the originator
of Fat Transfer (Autologous Fat Transplantation, AFT). His landmark presentation of Fat Transfer Using Liposuction Techniques
(1984) established this procedure for breast augmentation, facial rejuvenation, hand rejuvenation and a host of reconstructive
procedures. He is board certified by the American Board of Plastic Surgery and the American Board of Cosmetic Surgery. He is a
member of the American Society of Plastic Surgery and the American Academy of Cosmetic Surgery. Dr. Bircoll is retired from 25
years of private practice in Beverly Hills, California. He is currently actively lecturing and teaching the techniques of Fat
Transfer and Fat Storage for stem cell extraction, as well as cosmetic and reconstructive applications. Dr. Bircoll recently presented
the latest application of his Fat Transfer/Storage/Serial Injection concepts for breast cancer prevention surgery.
| · | Burt
D. Ensley, Ph.D. Dr. Ensley is the Chief Executive Officer and Chairman of Protein Genomics, Inc. He previously served
as Chief Executive Officer of Phytotech, Inc. and President of NuCycle Therapy, Inc. prior to their sale. In addition, Dr. Ensley
headed the Specialty Chemicals Group at Amgen, Inc. for nearly a decade. He holds a PhD in Microbiology from University of Georgia;
is a Fellow of the American Academy of Microbiology; served on the BIO Directorate Board of the National Science Foundation; and
is the Board Co-Chair of the University of Arizona’s BIO5 Institute. Dr. Ensley holds 19 issued U.S. patents. |
Dr.
Mittman currently serves as a senior partner of Seaview Orthopaedic and Medical Associates (SOMA) located in Ocean, New Jersey.
He has assembled a team of highly qualified board certified, fellowship trained physicians to practice at SOMA specializing in
general orthopaedics, as well as surgery of the Spine, Hand/Wrist, Knee/Shoulder, Total Joints, Foot and Ankle, Sports Medicine,
Pain Management and Osteoporosis. SOMA currently operates six locations committed to providing quality care in Monmouth and Ocean
Counties. After earning a Bachelor of Arts degree at John Hopkins University, Dr. Mittman earned his Medical Degree at the Albert
Einstein College of Medicine in New York and completed orthopaedic training in 1978 at Montefiore Hospital in New York. He is
a member of the New Jersey Orthopaedic Society, Orthopaedic Surgeons of New Jersey, Monmouth County Medical Society and the American
College of Sports Medicine.
Mr.
Davis is currently a partner in and the Chief Operating Officer of Novare, LLC. NovareBiologistics was created to meet the need
of transporting and storing laboratory materials, including biological samples at required temperature anywhere within the U.S.
Over the past 20 years, Mr. Davis has concentrated on business development and sales in biotechnology, manufacturing and software
technology. Previously, he was primarily involved in retailing.
Corporate
Information
Our
principal executive offices are located at 1 Meridian Road, Eatontown, New Jersey 07724 and our telephone number is (732) 747-1007.
Our website is www.americancryostem.com. We also lease and operate a tissue processing laboratory in Mount Laurel,
New Jersey at the Burlington County College Science Incubator located on the Burlington County College campus. Our laboratory
website address is www.acslaboratories.com.
Employees
Currently,
we have six employees and continue to use consultants on an as needed basis. As we grow, we will need to attract an unknown number
of additional qualified employees, however we could be unsuccessful in attracting and retaining the persons needed.
Available
information
We
file electronically with the U.S. Securities and Exchange Commission (SEC) our annual reports on Form 10-K, quarterly reports
on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d)
of the Securities Exchange Act of 1934. The public can obtain materials that we file with the SEC through the SEC’s website
at http://www.sec.gov or at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. Information
on the operation of the Public Reference Room is available by calling the SEC at 800-SEC-0330.
Item
1A. Risk Factors
To
date we have generated only minimal operating revenues. Our recurring losses from operations and negative cash flows from operations
raise substantial doubt about our ability to continue as a going concern and as a result, our independent registered public accounting
firm included an explanatory paragraph in its report on our financial statements for the fiscal year ended September 30, 2015
with respect to this uncertainty which is included in the 2015 10K. Substantial doubt about our ability to continue as a going
concern may create negative reactions to the price of our Common Stock and we may have a more difficult time obtaining financing.
We
expect to incur increased operating expenses for the foreseeable future. The amount of net losses and the time required for us
to reach and sustain profitability are uncertain. The likelihood of our success must be considered in light of the problems, expenses,
difficulties, and delays frequently encountered in connection with a development stage business, including, but not limited to,
uncertainty as to development and the time required for our planned services to become available in the marketplace. There can
be no assurance that we will ever generate revenues or achieve profitability at all or on any substantial basis. These matters
raise substantial doubt about our ability to continue as a going concern. If we cease or curtail our development activities, it
is highly likely that you would lose your entire investment in our Company.
We
will require substantial additional capital to pursue our business plan.
We
have incurred negative cash flows since inception from our developmental activities, and at this time as well as for the foreseeable
future will finance (until we can generate sufficient revenues, if ever, to cover expenses) our activities and overhead expenses
from any revenues we generate and through the issue and sale of debt and/or equity securities. The recoverability of the costs
incurred by us to date is highly uncertain and is dependent upon, among other items, achieving commercial production and sales
of our services, of which no assurances can be given. Our prospects must be considered in light of the risks, expenses and difficulties
which are frequently encountered by companies in the development stage in the emerging industry that we hope to commence operations
in.
We
have financed our development activities and expenses since inception through the sale of our debt and equity securities. Our
capital requirements will depend on many factors, including, among other things, the cost of developing our business and marketing
activities, the efficacy and effectiveness of our proposed services, costs (whether or not foreseen), the length of time required
to collect accounts receivable we may in the future generate, competing technological and market developments and acceptance.
Changes in our proposed business or business plan could materially increase our capital requirements. We cannot assure you that
our proposed plans will not change or that changed circumstances will not result in the depletion of our capital resources more
rapidly than currently anticipated.
Even
if we obtain funding, we still will need to obtain substantial additional financing to, among other things, fund the future development
of any services we attempt to undertake and for general working capital purposes. Any additional equity financing, if available,
may be dilutive to stockholders and any such additional equity securities may have rights, preferences or privileges that are
senior to those of the holders of shares of our Common Stock. Debt financing, if available, will require payment of interest and
may involve our granting security interests on our assets and restrictive covenants that could impose limitations on our operating
flexibility.
Our
ability to obtain needed financing may be impaired by such factors as the capital markets, our capital structure, our development
stage, the lack of an active market for shares of our Common Stock, and our lack of profitability, all of which would impact the
availability or cost of future financings. We cannot assure prospective investors that we will be able to obtain requisite financing
in a timely fashion or at all and, if obtained, on acceptable terms. Our inability to obtain needed financing on acceptable terms
would have a material adverse effect on the implementation of our proposed business plan.
Statements
concerning our future plans and operations are dependent on our ability to secure adequate funding and the absence of unexpected
delays or adverse developments. We may not be able to secure required funding.
The
statements concerning future events or developments or our future activities, such as current or planned research and development
activities, anticipated products and services, anticipated commercial introduction of products and services, and other statements
concerning our future operations and activities, are forward-looking statements that in each instance assume that we are able
to obtain sufficient funding in the near term and thereafter to support such activities and continue our operations and planned
activities in a timely manner. There can be no assurance that this will be the case. Also, such statements assume that there are
no significant unexpected developments or events that delay or prevent such activities from occurring. Failure to timely obtain
sufficient funding, or unexpected development or events, could delay the occurrence of such events or prevent the events described
in any such statements from occurring which could adversely affect our business, financial condition and results of operations.
We
have significant payment obligations under certain Notes due between January through July 2015. Any non-payment of the Notes when
due in the absence of an extension of the maturity date would constitute event of default under the Notes, and our financial condition
may be adversely affected.
As
of September 30, 2014, the Company had issued and outstanding $596,000 aggregate principal amount of Bridge Notes, which mature,
between January through July 2015 and bear interest at the rate of 8% per annum and $159,500 aggregate principal amount of Convertible
Notes which mature in September 2014, which Convertible Notes are convertible into shares of Common Stock and the rate of one
(1) share of Common Stock for each $0.35 of principal amount and/or interest so converted, and 397,500 of 8% convertible notes
which mature in September of 2016 and are convertible into shares of Common Stock and the rate of one (1) share of Common Stock
for each $0.30 of principal amount and/or interest so converted, and $50,000 of 8% convertible notes which mature in July of 2017
and are convertible into shares of Common Stock and the rate of one (1) share of Common Stock for each $0.30 of principal amount
and/or interest so converted No assurances can be given that the Company will have sufficient funds to repay the principal and/or
interest on such Bridge Notes when due or on the Convertible Notes such Convertible Notes are converted into Common Stock prior
to maturity. In such event, we might be subject to, among other things, non-payment claims of the Note holders, and our financial
condition may be adversely affected.
Our
limited operating history may make it difficult to evaluate our business and our future viability.
We
are in the relatively early stage of operations and have only a limited operating history on which to base an evaluation of our
business and prospects. Even if we successfully obtain additional funding, we are subject to the risks associated with development
stage companies with a limited operating history, including: the need for additional financing; the uncertainty of research and
development efforts; successful commercialization of our products and services; market and customer acceptance of our products
and services; unexpected issues with federal or state regulatory authorities; competition from larger organizations; dependence
on key personnel; uncertain patent or other intellectual property protection; fluctuations in expenses; and dependence on corporate
partners and collaborators. Any failure to successfully address these risks and uncertainties could seriously harm our business
and prospects. We may not succeed given the technological, marketing, strategic and competitive challenges we will face. The likelihood
of our success must be considered in light of the expenses, difficulties, complications, problems and delays frequently encountered
in connection with the growth of a new business, the continuing development of new drug technology, and the competitive and regulatory
environment in which we operate or may choose to operate in the future.
Many
of our products, services and technologies are in early stages of development.
Processing
and cryogenic storage of adipose tissue and stem cells, and application development is in the early stages of development, and
there can be no assurance that our business will be successful. Further, potential products based upon individuals’ stem
cells will require extensive additional research and development before any commercial introduction. There can be no assurance
that any future research and development will result in viable products or meet efficacy standards.
Cell
therapy is a developing field and a significant market for our services has yet to emerge in the US.
Cell
therapy and regenerative medicine is a developing field, with we believe few cell therapy products or services approved for clinical
and/or commercial use. We are wholly dependent on the acceptance of cell therapy (and specifically stem cells) to develop into
a large and profitable industry. We hope to develop services related to the collection, processing, storage of stem cells and
application development. We believe the market for stem cell and tissue-based therapies is in its infancy, substantially research
oriented and financially speculative and has yet to achieve substantial commercial success. Stem cell products and services may
in general be susceptible to various risks, including undesirable and unintended side effects, unintended immune system responses,
inadequate therapeutic efficacy, lack of acceptance by physicians, hospital and consumers, or other characteristics that may prevent
or limit their approval or commercial use. Management believes that the demand for tissue processing and stem cell processing
and the number of people who may use cell or tissue-based therapies is difficult, if not impossible, to forecast. Our success
is dependent on, among other items, the establishment of a market for our proposed services and our ability to capture a share
of this market.
Our
proposed services may not attain commercial acceptance absent endorsement by physicians.
Our
proposed services will compete against individual adipose tissue and cellular samples derived from alternate sources, such as
bone marrow, umbilical cord blood and perhaps embryos. We believe that physicians and hospitals are historically slow to adopt
new technologies like ours, whatever the merits, when older technologies continue to be supported by established providers. Overcoming
such inertia often requires very significant marketing expenditures or definitive product performance and/or pricing superiority.
Management currently believes physicians’ and hospitals’ inertia and skepticism to be a significant barrier as we
attempt to gain market penetration with our proposed services. Failure to achieve market acceptance of our proposed services would
have a material adverse effect on our future prospects.
If
we should in the future become required to obtain regulatory approval to market and sell our proposed services we will not be
able to generate any revenues until such approval is received.
The
medical industry is subject to stringent regulation by a wide range of authorities. We are required to have licenses in two states
and have obtained tissue bank licenses to market and support our services in New York and California as well as annual registration
with the FDA as a tissue bank. While we believe that, given our proposed business, we are not presently required to obtain additional
state and federal regulatory approval to market our services we cannot predict whether regulatory clearance will be required in
the future and, if so, whether such clearance will at such time be obtained, whether for the stem cells and/or any other services
that we are developing or may attempt to develop. Should such regulatory approval in the future be required, our services may
be suspended or may not be able to be marketed and sold in the United States until we have completed the regulatory clearance
process as and if implemented by the FDA. Satisfaction of regulatory requirements typically takes many years, is dependent upon
the type, complexity and novelty of the product or service and would require the expenditure of substantial resources.
If
regulatory clearance of a service we propose to provide is granted, this clearance may be limited to those particular states and
conditions for which the service is demonstrated to be safe and effective, which would limit our ability to generate revenue.
We
cannot ensure that any service developed by us will meet all of the applicable regulatory requirements needed to receive marketing
clearance. Failure to obtain regulatory approval will prevent commercialization of our services where such clearance is necessary.
There can be no assurance we will obtain regulatory approval of our proposed services that may require it.
Our
facilities may require compliance with PHS and FDA regulations regarding current Good Manufacturing Protocols and there is no
assurance we are in and/or in the future will be in compliance with these protocols or that the PHS or FDA may find deficiencies
upon inspection of our facility.
The
Company has developed its processing methodologies, testing and Mount Laurel laboratory facilities which the Company believes
may be required to be in compliance with all current Good Manufacturing Practices and current Good Tissue Practices (cGTP) as
defined by the United States Public Health Service Act (“PHS” or the “PHS Act”)
and the Food and Drug Administration (“FDA”) regulations as they relate to the operation of a tissue
processing and storage facility. While we believe such facilities are in compliance with such regulations, no assurance can be
given that we are in fact in compliance and/or in the future will be in compliance with these regulations or that upon inspection
by PHS and/or FDA that we will not be required to amend our procedures or limit our operations based upon the finding of the inspection.
As
and if we evolve from a company primarily involved in the research and development of our technology into one that is also involved
in the commercialization of our technology, we may have difficulty managing our growth and expanding our operations.
As
and if our business grows, we will in all likelihood need to add employees and enhance our management, systems and procedures.
We may need to successfully integrate our internal operations with the operations of various third party services providers to
produce and market commercially viable products. We may also need to manage additional relationships with various collaborative
partners, suppliers and other organizations. Expanding our business may place a significant burden on our management and operations.
We may not be able to implement improvements to our management information and control systems in an efficient and timely manner
and we may discover deficiencies in our existing systems and controls. Our failure to effectively respond to such changes may
make it difficult for us to manage our growth and expand our operations.
We
currently are wholly dependent on John Arnone and Anthony Dudzinski; Conflicts of Interest.
We
currently are wholly dependent on John Arnone and Anthony Dudzinski, our only executive officers and directors. Our future performance
will depend on the continued services of such persons and our ability to retain such persons and to hire additional qualified
persons. The loss of either of Mr. Arnone or Mr. Dudzinski, or both, would materially and adversely affect our proposed business.
We have entered into employment agreements with Mr. Arnone or Mr. Dudzinski who have waived portions of their compensation for
fiscal 2013 and 2014. There are no assurances they will continue to do so. The employment agreements among other terms permit
each of Mr. Arnone and Mr. Dudzinski to conduct other business activities outside of their employment with us. Each such employment
agreement terminates in October 2017.
We
have not obtained any “key-man” life insurance policies nor do we presently plan to obtain or maintain any such policies
on Mr. Arnone, Mr. Dudzinski or any other of our employees.
Mr.
Arnone owns the majority of the issued and outstanding voting stock of Personal Cell Science, a Florida corporation (“PCS”).
PCS is in the cosmetic business and has entered into a contract manufacturing and royalty agreement with us to manufacture conditioned
medium. We also receive a royalty of 10% of the gross sales of any products sold by PCS containing the conditioned medium that
we manufacture. Mssrs. Arnone and Dudzinski collectively beneficially own in excess of 50.1% of our issued and outstanding voting
stock and as a result have the ability to directly and/or indirectly make all decisions for us. Mr. Arnone is also the CEO of
Regenerative BioTherapy Corp. Regenerative BioTherapy Corp, a Florida corporation which entered into a licensing Agreement with
the Company in September of 2014. The licensing agreement Permits Regenerative BioTheray the use of the Company’s Standard
Operating Procedures, Quality Management and General Operations procedures and process for the Company’s product lines and
IP; to construct and operate a laboratory and treatment facility in the Caribbean.
We
may in the future seek to expand our business relationship with, and/or acquire PCS and/or Regenerative BioTherapy Corp.. Management
cannot assure you that any such business relationship or acquisition, if consummated, would be on terms favorable to us.
We
may be unable to protect our intellectual property from infringement by third parties, and third parties may claim that we are
infringing on their intellectual property, either of which could materially and adversely affect us.
We
intend to rely on patent protection, trade secrets, technical know-how and continuing technological innovation to protect our
intellectual property, and we expect to require any employees, consultants and advisors that we may hire or engage in the future
to execute confidentiality and assignment of inventions agreements in connection with their employment, consulting or advisory
relationships. There can be no assurance, however, that these agreements will not be breached or that we will have adequate remedies
for any such breach.
Despite
our efforts to protect our intellectual property, third parties may infringe or misappropriate our intellectual property or may
develop intellectual property competitive with ours. Our competitors may independently develop similar technology or otherwise
duplicate our proposed processes or services. As a result, we may have to litigate to enforce and protect our intellectual property
rights to determine their scope, validity or enforceability. Intellectual property litigation is particularly expensive, time-consuming,
diverts the attention of management and technical personnel and could result in substantial cost and uncertainty regarding our
future viability. The loss of intellectual property protection or the inability to secure or enforce intellectual property protection
would limit our ability to produce and/or market our services in the future and would likely have an adverse effect on any revenues
we may in the future be able to generate by the sale or license of such intellectual property.
We
may be subject to costly litigation in the event our future services or technology infringe upon another party’s proprietary
rights. Third parties may have, or may eventually be issued, patents that would be infringed by our technology. Any of these third
parties could make a claim of infringement against us with respect to our technology. We may also be subject to claims by third
parties for breach of copyright, trademark or license usage rights. Any such claims and any resulting litigation could subject
us to significant liability for damages or injunctions precluding us from utilizing our technology or services or marketing or
selling any products or services under the same. An adverse determination in any litigation of this type could require us to design
around a third party’s patent, license alternative technology from another party or otherwise result in limitations in our
ability to use the intellectual property subject to such claims.
Risks
Related to Our Common Stock
We
are authorized to issue 300,000,000 shares of Common Stock and 50,000,000 shares of “blank check” preferred stock,
the issuance of which could, among other things, reduce the proportionate ownership interests of current shareholders.
We
are authorized to issue 300,000,000 shares of Common Stock and 50,000,000 shares of “blank check” preferred stock.
As of June 30, 2015, there were 34,705,451 shares of Common Stock (excluding 12,321,000 shares issuable upon exercise of
all issued and outstanding stock options and warrants, and 586,666 shares issuable on the conversion of all outstanding Convertible
Notes, and no shares of preferred stock were issued and outstanding. Our board of directors has the ability, without seeking shareholder
approval, to issue additional shares of Common Stock and/or to designate, establish the terms and conditions of, and issue shares
of preferred stock for such consideration, if any, as the board of directors may determine. Any such shares of preferred stock
could have dividend, liquidation, conversion, voting or other rights, which could adversely affect the voting power or other rights
of the holders of shares of Common Stock. In the event of such issuance, the preferred stock could, among other items, be used
as a method of discouraging, delaying or preventing a change in control of our Company, which could have the effect of discouraging
bids for our Company and thereby prevent security-holders from receiving the maximum value for their shares of our Common Stock.
Our
Common Stock is currently traded on the OTCQB and is subject to additional trading restrictions as a “penny stock,”
which could adversely affect the liquidity and price of such stock. If our Common Stock remains subject to the SEC’s penny
stock rules, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities
may be adversely affected.
Our
Common Stock currently trades on the OTCQB. The OTCQB may be viewed by investors as a less desirable, and less liquid, marketplace.
As a result, an investor may find it more difficult to purchase, dispose of or obtain accurate quotations as to the value of our
Common Stock.
Because
our Common Stock is not listed on any national securities exchange, such shares will also be subject to the regulations regarding
trading in “penny stocks,” which are those securities trading for less than $5.00 per share, and that are not otherwise
exempted from the definition of a penny stock under other exemptions provided for in the applicable regulations. The following
is a list of the general restrictions on the sale of penny stocks:
| · | Before
the sale of penny stock by a broker-dealer to a new purchaser, the broker-dealer must determine whether the purchaser is suitable
to invest in penny stocks. To make that determination, a broker-dealer must obtain, from a prospective investor, information regarding
the purchaser’s financial condition and investment experience and objectives. Subsequently, the broker-dealer must deliver
to the purchaser a written statement setting forth the basis of the suitability finding and obtain the purchaser’s signature
on such statement. |
| · | A
broker-dealer must obtain from the purchaser an agreement to purchase the securities. This agreement must be obtained for every
purchase until the purchaser becomes an “established customer.” |
| · | The
Exchange Act requires that before effecting any transaction in any penny stock, a broker-dealer must provide the purchaser with
a “risk disclosure document” that contains, among other things, a description of the penny stock market and how it
functions and the risks associated with such investment. These disclosure rules are applicable to both purchases and sales by
investors. |
| · | A
dealer that sells penny stock must send to the purchaser, within 10 days after the end of each calendar month, a written account
statement including prescribed information relating to the security. |
These
requirements can severely limit the liquidity of securities in the secondary market because fewer brokers or dealers are likely
to be willing to undertake these compliance activities. As a result of our Common Stock not being listed on a national securities
exchange and the rules and restrictions regarding penny stock transactions, an investor’s ability to sell to a third party
and our ability to raise additional capital may be limited. We make no guarantee that market-makers will make a market in our
Common Stock, or that any market for our Common Stock will continue.
Our
two (2) principal stockholders control us, and your interests as a stockholder may conflict with the interests of those persons.
Based
on the number of outstanding shares of our Common Stock held by our stockholders as of September 30, 2015, our two (2) directors,
executive officers and their respective affiliates beneficially owned in excess of 50.1% of our outstanding shares of Common Stock.
As a result, those stockholders have the ability to control, among other items, the outcome of all matters submitted to our stockholders
for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets.
The interests of these persons may not always coincide with our interests or the interests of our other stockholders. This concentration
of ownership could harm the market price of our Common Stock by (i) delaying, deferring or preventing a change in corporate control,
(ii) impeding a merger, consolidation, takeover or other business combination involving us, and/or (iii) discouraging a potential
acquirer from attempting to obtain acquire us. The control held over us by such 2 persons may adversely affect the trading price
of our Common Stock due to investor’s awareness of conflicts of interest.
Our
stockholders may experience significant dilution as a result of any additional financing using our securities.
We
will need to raise significant additional capital in order to maintain and continue our operations. To the extent that we raise
additional funds by issuing equity securities or securities convertible into or exercisable for equity securities, our stockholders
may experience significant dilution and we may issue securities with better terms than those offered hereby.
We
have not paid dividends on our Common Stock in the past and do not expect to pay dividends on our Common Stock for the foreseeable
future. Any return on investment may be limited to the value of our Common Stock.
No
cash dividends have been paid on our Common Stock, and we do not expect to pay cash dividends on our Common Stock in the foreseeable
future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors
as our board of directors may consider relevant. If we do not pay dividends, our Common Stock may be less valuable because a return
on a stockholder’s investment will only occur if our stock price appreciates.
A
sale of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline and may impair our
ability to raise capital in the future.
Our
Common Stock is currently traded on the OTCQB, and there have been and may continue to be periods when it could be considered
“thinly-traded,” meaning that the number of persons interested in purchasing our Common Stock at or near bid prices
at any given time may be relatively small or non-existent. Finance transactions resulting in a large amount of newly issued shares
that become readily tradable or other events that cause stockholders to sell shares, could place downward pressure on the trading
price of our stock. In addition, the lack of a robust resale market may require a stockholder who desires to sell a large number
of shares of Common Stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market
price of our stock. If our stockholders sell, or the market perceives that our stockholders intend to sell for various reasons,
substantial amounts of our Common Stock in the public market, the market price of our Common Stock could decline. Sales of a substantial
number of shares of our Common Stock may make it more difficult for us to sell equity or equity-related securities in the future
at a time and price that we deem reasonable or appropriate.
The
Company may not have complied with various state securities laws in connection with prior issuances/sales of its securities.
Since
April 2011, the date of the closing of the Asset Purchase, through September 30, 2015, the Company sold approximately $3,412,500
gross amount of its equity and debt securities. In connection with such sales, the Company may have violated various state securities
laws. If the Company was determined by a court, FINRA or regulatory body with the required jurisdiction to have violated such
laws, any such violation could result in the Company being required to offer rescission rights to each such prior purchase from
the Company to rescind such purchases and pay to the prior purchaser an amount of funds equal to the purchase price paid by such
prior investors plus interest from the date of any such purchase. No assurances can be given the Company will, if it is required
to offer such purchasers rescission right, have sufficient funds to pay the prior purchasers the amount required. In addition,
if the Company violated one or more securities laws of a state in connection with prior offers and/or sales of its securities,
each such state could bring an enforcement, regulatory and/or other legal action against the Company which, among other things,
could result in the Company having to pay substantial fines, not being able to sell securities in such states in the future and/or
having a determination made by any such states against the Company that the Company failed to comply with such states’ securities
laws, which could result in the Company, among other untoward effects including those set forth above, not being able to have
its Common Stock be eligible for continued quotation on the OTCQB and/or other trading markets and/or mediums that the Common
Stock is then trading and/or eligible for quotation on and/or in the future seeks to be quoted or traded on.
As
a “thinly-traded” stock, large sales can place downward pressure on our stock price.
Our
stock experiences periods when it could be considered “thinly traded.” Financing transactions resulting in a large
number of newly issued shares that become readily tradable, or other events that cause current shareholders to sell shares, could
place further downward pressure on the trading price of our stock. In addition, the lack of a robust resale market may require
a shareholder who desires to sell a large number of shares to sell the shares in increments over time to mitigate any adverse
impact of the sales on the market price of our stock.
Shares
eligible for future sale may adversely affect the market for our Common Stock.
As
of September 30, 2015, we had 12,321,000 shares of Common Stock issuable upon exercise of all outstanding stock options and warrants,
and, 1,940,001 shares issuable on the conversion of outstanding Convertible Notes. If and when these securities are exercised
or converted into shares of our Common Stock, the number of our shares of Common Stock outstanding will increase. Such increase
in our outstanding shares, and any sales of such shares into the public market, could have a material adverse effect on the market
for our Common Stock and the market price of our Common Stock.
In
addition, from time to time, certain of our shareholders may be eligible to sell all or some of their shares of Common Stock by
means of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject
to certain limitations. In general, pursuant to Rule 144, after satisfying a six month holding period: (i) affiliated shareholders
(or shareholders whose shares are aggregated) may, under certain circumstances, sell within any three month period a number of
securities which does not exceed the greater of 1% of the then outstanding shares of common stock and (ii) non-affiliated shareholders
may sell without such limitations, provided we are current in our public reporting obligations. Rule 144 also permits the sale
of securities by non-affiliates that have satisfied a one year holding period without any limitation or restriction. Any substantial
sale of our common stock pursuant to Rule 144 or pursuant to any resale prospectus may have a material adverse effect on the market
price of our securities.
Item
1B. Unresolved Staff Comments
Not
applicable.
Item
2. Description of Property
We
currently rent office space at 1 Meridian Road, Eatontown, NJ 07724 for our corporate offices. Additionally we rent laboratory
space at the Burlington County College Science Incubator 100 Technology Way, Mount Laurel NJ 08054. Our laboratory facility consists
of approximately 1300 square feet of leased space located in the science incubator on the Campus of the Burlington Community College
located in Mount Laurel, New Jersey.
Item
3. Legal Proceedings
We
are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or
results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our
subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies
or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material
adverse effect.
Item
4. Mine Safety Disclosures
Not
applicable.
PART
II
Item
5. Market for Common Equity and Related Stockholder Matters
(a)
Market Information
Our
common stock was listed on the OTCQB under the symbol “RAPP” on November 12, 2010. In June 2011, we changed our name
to American CryoStem Corporation and since June 15, 2011, our common stock has traded under the stock symbol “CRYO”
on the OTCQB. The following table shows the reported high and low closing prices per share for our common stock for each quarterly
period as noted. The over-the-counter market quotations set forth for our common stock reflect interdealer prices, without retail
mark-up, mark-down or commission and may not necessarily represent actual transactions.
Quarter ended | |
High | | |
Low | |
December 31, 2014 | |
$ | 0.50 | | |
$ | 0.23 | |
March 31, 2015 | |
$ | 0.49 | | |
$ | 0.23 | |
June 30, 2015 | |
$ | 0.50 | | |
$ | 0.20 | |
September 30, 2015 | |
$ | 0.35 | | |
$ | 0.11 | |
(b)
Holders of Common Equity
As
of September 30, 2015, there were approximately 119 holders of record of our common stock. This figure does not take into account
those shareholders whose certificates are held in the name of broker-dealers or other nominees.
(c)
Dividend Information
We
have never paid any cash dividends on our common shares, and we do not anticipate that we will pay any dividends with respect
to those securities in the foreseeable future. Our current business plan is to retain any future earnings to finance the expansion
development of our business.
(d)
Sales of Unregistered Securities
During
fiscal year 2014, option holders exercised 170,000 options and the Company issued 170,000 shares of common stock and received
proceeds of $24,500.
During
fiscal year 2014, holders of convertible notes converted $152,300 of convertible notes and the Company issued 435,143 shares of
common stock.
During
fiscal year 2015, debenture holders converted $17,500 of convertible notes into 54,286 shares of common stock.
During
fiscal year 2015, officers of the Company exercised 1,460,000 options at $0.01 and received 1,460,000 shares.
During
fiscal year 2015, the Company issued 70,000 shares of common stock to pay $21,000 of the bridge loan discussed in Note
6.
As part of this payment, the Company issued 4,542 shares to pay interest due on the bridge loan.
During
fiscal year 2015, the Company issued 175,759 shares of common stock and received proceeds of $55,000.
During
fiscal year 2015, the Company issued 50,000 to a charitable organization and recognized and expense of $12.500.
(e)
Securities Authorized For Issuance Under Equity Compensation Plans
During
fiscal year 2014, option holders exercised 170,000 options and the Company issued 170,000 shares of common stock and received
proceeds of $24,500.
During
the fiscal year ended September 30, 2013, we issued 50,000 common shares to an advisory board member in connection with the exercise
of 50,000 options issued at an exercise price of $0.15 under the 2011 American CryoStem Corporation Stock Option Plan. The Company
accepted a $7,500 balance due to the option holder in payment for the Option exercise.
The
Company applies ASC 718, “Accounting for Stock-Based Compensation” to account for its option issues. Accordingly,
all options granted are recorded at fair value using a generally accepted option pricing model at the date of the grant. For purposes
of determining the option value at issuance, the fair value of each option granted is measured at the date of the grant by the
option pricing model with the following assumptions:
| |
FY 2015 | | |
FY 2014 | |
| |
| | |
| |
Dividend yield | |
| 0.00 | % | |
| 0.00 | % |
Risk free interest rate | |
| 0.25 | % | |
| 0.25 | % |
Volatility | |
| 26.37 | % | |
| 48.39 | % |
The
fair values generated by option pricing model may not be indicative of the future values, if any, that may be received by the
option holder.
During
fiscal year 2015, the Company issued 3,525,000 options to employees, the holders of the bridge notes, and other professionals.
As a result, the Company recorded labor expense of $399,432, in its statement of operations.
Transfer
Agent
Our
transfer agent is Olde Monmouth Stock Transfer Co., Inc. located at 200 Memorial Parkway, Atlantic Highlands, New Jersey 07716.
Its contact phone is 732-872-2727.
Item
6. Selected Financial Data
Not
applicable.
Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This
annual report on Form 10-K and other reports filed by American CryoStem Corporation (the “Company”) from time to time
with the U.S. Securities and Exchange Commission (the “SEC”) contain or may contain forward-looking statements and
information that are based upon beliefs of, and information currently available to, the Company’s management as well as
estimates and assumptions made by Company’s management. Readers are cautioned not to place undue reliance on
these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in the
filings, the words “anticipate,” “believe,” “estimate,” “expect,” “future,”
“intend,” “plan,” or the negative of these terms and similar expressions as they relate to the Company
or the Company’s management identify forward-looking statements. Such statements reflect the current view of
the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the
risks contained in the “Risk Factors” section of the this Annual Report on Form 10-K., relating to the Company’s
industry, the Company’s operations and results of operations, and any businesses that the Company may acquire. Should
one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results
may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.
Although
the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee
future results, levels of activity, performance, or achievements. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these
statements to actual results.
Our
financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).
These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments
and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments
and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and
liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods
presented. Our financial statements would be affected to the extent there are material differences between these estimates and
actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does
not require management’s judgment in its application. There are also areas in which management’s judgment in selecting
any available alternative would not produce a materially different result. The following discussion should be read in conjunction
with our consolidated financial statements and notes thereto appearing elsewhere in this report.
Background
We
were incorporated in the State of Nevada on March 13, 2009. On April 20, 2011, we acquired, through our wholly owned subsidiaryAmerican
CryoStem Acquisition Corporation, substantially all of the assets from, and assumed substantially all of the liabilities of, ACS
Global,Inc. (“ACS”) in exchange for our issuance of 21,000,000 shares of our common stock, par value $0.001 per share,
to ACS (the “AssetPurchase”). We filed a Current Report on Form 8-K with the Securities and Exchange Commission on
April 27, 2011 disclosing the AssetPurchase and certain related matters including, but not limited to, the appointment of our
present officers and directors as well as the resignationby the former chief executive officer and sole director. Our fiscal year
ends September 30 of each calendar year.
Overview
American
CryoStem Corporation, which we refer to as “we,” “us,” “our” and “our Company,”
is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services
with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous
adipose-derived regenerative cells (ADRCs). We maintain a strategic portfolio of intellectual property and patent applications
that form our Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes,
clinical services and international licensing opportunities. Through our ACS Laboratories division, we operate an FDA registered,
compliant human tissue processing, cryostorage and cell culture and differentiation media development facility in Mount Laurel,
New Jersey at the Burlington County College Science Incubator.
Our
growth strategy is centered on expanding our research and development through scientific collaborations to fully capitalize on
(1) scientific breakthroughs that have been rapidly shaping the fast growing Regenerative and Personalized Medicine industries;
(2) to provide these growth industries with a standardized cell processing platform and, (3) to enhance the delivery of healthcare
through cellular-based therapies and applications which address disease treatment, wound and burn healing, joint repair and management,
and personalized health and beauty care.
Through
our ACS Laboratories division, our Company operates its flagship FDA registered, human tissue processing, cryostorage and cell
culture and differentiation media development facility in Mount Laurel, New Jersey. On a mission to fulfill the pressing need
to set a global gold standard for end-to-end clinical collection, processing, tracking and storage, American CryoStem has spent
nearly six years designing and constructing the necessary clinical framework capable of replicating its protocols in markets around
the world.
In
June 2013, our Company received approvals from the Institutional Review Board (IRB) of the International Cell Surgical Society
for the Company’s processing protocols for isolating Stromal Vascular Fraction (SVF) or ADSCs from a patient’s adipose
tissue; and for culturing mesenchymal stem cells from adipose tissue. These protocols provide validated testing methods necessary
to move the clinical investigative process towards uniform disease treatments’ and provide the collection of processing
and outcome data required by prevailing FDA regulations and guidance for approval of regenerative cellular therapies, including
potency (cell count), contamination testing and cell viability. The Company obtained approval for these IRBs with the Institute
of Regenerative Cellular Medicine (IRCM) in 2014 and renewed the IRB with the IRCM in 2015.
Today,
American CryoStem is focused on securing licensing arrangements with qualified partners around the world to institute and operate
its turnkey clinical laboratories that are properly equipped for processing and storing adipose tissue and ADSCs for use in Regenerative
and Personalized Medicine applications.
Cash
Requirements
We
will require additional capital to fund marketing, operational expansion, processing staff training, as well as for working capital.
We are attempting to raise sufficient funds would enable us to satisfy our cash requirements for a period of the next 12 to 24
months. We have minimal long term debt and have been able to meet our past financial obligations. In order to finance further
market development with the associated expansion of operational capabilities for the time period discussed above, we will need
to raise additional working capital. However, we cannot assure you we can attract sufficient capital to enable us to fully fund
our anticipated cash requirements during this period.In addition, we cannot assure you that the requisite financing, whether over
the short or long term, will be raised within the necessary time frame or on terms acceptable to us, if at all. Should we be unable
to raise sufficient funds we may be required to curtail our operating plans if not cease them entirely. As a result, we cannot
assure you that we will be able to operate profitably on a consistent basis, or at all, in the future.
In
order to move our Company through its next critical growth phase of development and commercialization and to ensure we are in
position to support our research collaborations and market penetration strategies, Management continues to seek new investment
into the Company from existing and new investors with particular emphasis on identifying the best deal structure to attract and
retain meaningful capital sponsorship from both the retail and institutional investing communities, while limiting dilution to
our current shareholders. Additionally during fiscal 2015, Management has focused its efforts on increasing sales and licensing
revenue and reducing expenses.
As
a result of these efforts by Management, we expended: $73,405 in professional fees (principally legal and accounting) during the
fiscal year ended September 30, 2015 down from $381,214 in Fiscal 2014, a decease of 80%. In Fiscal 2015 we spent $282,519 in
Research and Development down from $399,702 in Fiscal 2014 a decrease of 29% and Administrative Expenses of $1,038,385 in Fiscal
2015 down from $1,172,003, a decrease of 11%. Overall, we were able to decrease our net loss to $1,379,480 in Fiscal 2015 from
a net loss of $2,088,149 in Fiscal 2014, a reduction of approximately 34%. The Company's Gross Revenue increased to $338,910 in
Fiscal 2015 versus Gross Revenue of $120,956 in Fiscal 2014, an increase of 180%, and Accounts Receivable increased from $6,074
in Fiscal 2014 to $56,513 in Fiscal 2015. Management intends to continue its focus on increasing revenue and reducing costs in
Fiscal 2016.
Going
Concern
As
of the date of this annual report, there is substantial doubt regarding our ability to continue as a going concern as we have
not generated sufficient cash flow to fund our proposed stem cell business.
We
have suffered recurring losses from operations since our inception. In addition, we have yet to generate an internal cash flow
from our business operations or successfully raised the financing required to expand our business. As a result of these and other
factors, our independent auditor has expressed substantial doubt about our ability to continue as a going concern. Our future
success and viability, therefore, are dependent upon our ability to generate capital financing. The failure to generate sufficient
revenues or raise additional capital may have a material and adverse effect upon us and our shareholders.
Our
plans with regard to these matters encompass the following actions: (i) obtaining funding from new investors to alleviate our
working capital deficiency, and (ii) expanding sales of our products and services, (iii) increase Licensing transactions, Licensing
our products for manufacture and distribution, and, (iv) continuing our cost control efforts. Our continued existence is dependent
upon our ability to resolve our liquidity problems and achieve profitability in our current business operations. However, the
outcome of management’s plans cannot be ascertained with any degree of certainty. Our financial statements do not include
any adjustments that might result from the outcome of these risks and uncertainties.
Liquidity
and Capital Resources
As
of the fiscal year ended September 30, 2015, the Company had a cash balance of $9,059 and accounts receivable of $56,513. Our
principal source of funds has been sales of our securities. Should we be unable to raise sufficient funds, we will be required
to curtail our operating plans if not cease them entirely. We cannot assure you that we will generate the necessary funding to
operate or develop our business. Please see “Cash Requirements” above for our existing plans with respect to raising
the capital we believe will be required. In the event that we are able to obtain the necessary financing to move forward with
our business plan, we expect that our expenses will increase significantly as we attempt to grow our business. Accordingly, the
above estimates for the financing required may not be accurate and must be considered in light these circumstances.
There
was no significant impact on the Company’s operations as a result of inflation for the fiscal year ended September 30, 2015.
Off
Balance Sheet Arrangements
We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to investors.
Critical
Accounting Policies
We
prepare financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”), which requires
us to make estimates and assumptions that affect the amounts reported in our combined and consolidated financial statements and
related notes. We periodically evaluate these estimates and assumptions based on the most recently available information, our
own historical experience and various other assumptions that we believe are reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Since the use of estimates is an integral component of the financial reporting process, actual results could differ
from those estimates. Some of our accounting policies require higher degrees of judgment than others in their application. We
believe the following accounting policies involve the most significant judgments and estimates used in the preparation of our
financial statements.
Basis
of Presentation
Our
financial statements are presented on the accrual basis of accounting in accordance with generally accepted accounting principles
in the United State of America, whereby revenues are recognized in the period earned and expenses when incurred.
Management’s
Use of Estimates
The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from those estimates.
Long-Lived
Assets
We
review and evaluate our long-lived assets for impairment whenever events or changes in circumstances indicate that their net book
value may not be recoverable. When such factors and circumstances exist, we compare the assets’ carrying amounts against
the estimated undiscounted cash flows to be generated by those assets over their estimated useful lives. If the carrying amounts
are greater than the undiscounted cash flows, the fair values of those assets are estimated by discounting the projected cash
flows. Any excess of the carrying amounts over the fair values are recorded as impairments in that fiscal period.
Statement
of Cash Flows
For
purposes of the statement of cash flows, we consider all highly liquid investments (i.e., investments which, when purchased, have
original maturities of three months or less) to be cash equivalents.
Fair
Value of Financial Instruments
Our
financial instruments consist of cash and cash equivalents. The fair value of cash and cash equivalents approximates the recorded
amounts because of the liquidity and short-term nature of these items.
Recent
Accounting Pronouncements
We
have reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe that any future adoption
of such pronouncements will have a material impact on our financial condition or the results of our operations.
Item
7A. Quantitative and Qualitative Disclosures about Market Risk
We
do not hold any derivative instruments and do not engage in any hedging activities.
Item
8. Financial Statements
Our
financial statements are contained in pages F-1 through F-12 which appear at the end of this Annual Report.
Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item
9A. Controls and Procedures
(a)
Evaluation of Disclosure and Control Procedures
The
Company’s disclosure controls and procedures are designed to ensure (i) that information required to be disclosed by the
Company in the reports the Company files or submits under the Exchange Act are recorded, processed, summarized, and reported within
the time periods specified in the SEC’s rules and forms; and (ii) that information required to be disclosed by the Company
in the reports it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including
its principal executive officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure.
Our
principal executive officer and principal financial officer evaluated the effectiveness of the design and operation of our disclosure
controls and procedures as of December 31, 2015, and concluded that the disclosure controls and procedures were effective as a
whole.
(b) Management’s
Report on Internal Control over Financial Reporting
The
Company’s management is responsible for establishing and maintaining an adequate system of internal control over financial
reporting, as defined in Rule 13a-15(f) under the Exchange Act. The Company’s internal control over financial
reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”).
Because
of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance of such
reliability and may not prevent or detect misstatements. Also, projection of any evaluation of effectiveness to future
periods is subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
Management
has conducted, with the participation of our Chief Executive Officer and our Principal Accounting Officer, an assessment of the
effectiveness of our internal control over financial reporting as of December 31, 2015. Management’s assessment
of internal control over financial reporting used the criteria set forth in SEC Release 33-8810 based on the framework established
by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control over Financial
Reporting – Guidance for Smaller Public Companies. Based on this evaluation, Management concluded that our system of
internal control over financial reporting was effective as of December 31, 2015, based on these criteria.
(c)
Changes in Internal Control over Financial Reporting
There
were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange
Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.
(d)
Attestation Report of the Registered Public Accounting Firm
This
annual report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant
to an exemption for smaller reporting companies.
Item
9B. Other Information.
None.
PART
III
Item
10. Directors, Executive Officers, and Corporate Governance
The
following table and biographical summaries set forth information, including principal occupation and business experience, about
our directors and executive officers at September 30, 2015:
| |
| | |
| |
Officer and/or | |
Name | |
Age | | |
Position | |
Director Since | |
| |
| | |
| |
| |
John Arnone | |
| 58 | | |
Chairman and Chief Executive Officer | |
| 2011 | |
| |
| | | |
| |
| | |
Anthony F. Dudzinski | |
| 53 | | |
Chief Operating Officer and Director | |
| 2011 | |
| |
| | | |
| |
| | |
John DiFolco | |
| 31 | | |
Executive Vice President and Director of Marketing | |
| 2013 | |
John
Arnone – Chairman and Chief Executive Officer
Mr.
Arnone has been the Chairman of American CryoStem since 2008 and Chief Executive Officer since 2011. Mr. Arnone is also Chairman
and CEO of Personal Cell Sciences, Inc., a private Company that markets the U-Autologous line of skin care products and Regenerative
BioTherapy Corp, a private company that plans to establish a wellness treatment facility in the Caribbean. Prior to his involvement
in the life sciences/biotechnology industries, he spent 25 years in the investment banking/financial services industry as an investment
banker and a proactive investor. Over a 25 year period, Mr. Arnone founded, managed and operated two general securities broker-dealers
based in New York specializing in strategic planning, new business development and corporate finance. Over the years, he
has provided advisory and business management services as a founder, officer, director and/or shareholder to both mid-level and
development stage private and public companies. Mr. Arnone also co-founded and operated a global entertainment distribution corporation
with 120 employees, and under his guidance the Company was voted medium wholesaler of the year in the music industry (1997, 1998
and 2000) by the National Association of Recording Merchants. Mr. Arnone holds a degree in Business Administration and a Bachelors
of Art in Economics from Kean University in New Jersey.
Anthony
F. Dudzinski − Chief Operating Officer and Director
Mr.
Dudzinski is a founder of American CryoStem as well as its Chief Operating Officer. He is primarily focused on building and maintaining
the Company’s operational and laboratory infrastructure and their compliance with current regulations. Mr. Dudzinski has
been in the life sciences and biotechnology sector for more than eight years and has more than 25 years of experience in areas
of senior management with a variety of public and private companies. Beginning in the securities industry with a focus on regulatory
compliance and operations, he combined this experience with the biotechnology industry while building new investment vehicles
focused on life sciences and biotechnology companies in 2004. Mr. Dudzinski’s past positions include Chief Executive Officer,
President, Chief Operating Officer and Director of small and medium-sized organizations, including a publicly traded company with
approximately 300 employees. He was also the President and Chief Operating Officer of a privately operated, registered broker-dealer
with more than 175 sales associates. In addition to this experience, he was a founder and Chief Executive Officer of a number
of publicly available exchange traded funds; and the Founder, Chairman and Chief Operating Officer of a target date fund complex
and a registered investment company.
John
DiFolco –Executive Vice President & Director of Marketing
Mr.
DiFolco has served as American CryoStem’s Director of Marketing since 2008 and was named Executive Vice President in 2013.
His core focus is to create and implement marketing campaigns targeting prospective customers and business partners. Mr. DiFolco
has been has been involved directly and indirectly in creating and implementing marketing campaigns for various organizations
over the years. He has introduced new products and services to new markets and as a result increased overall awareness and revenue.
Mr. DiFolco is highly skilled in assessing the market landscape and determining and implementing tactical strategies to successfully
market a company’s services through multiple channels, including social networking, search engine marketing, local web searching
and grass roots print media campaigns. He has a deep understanding of technology, specifically web development and the creation
of digital media.
Compliance
with Section 16(A) of the Exchange Act
Section
16(a) of the Exchange Act requires the Company’s directors, executive officers and persons who beneficially own 10% or more
of a class of securities registered under Section 12 of the Exchange Act to file reports of beneficial ownership and changes in
beneficial ownership with the SEC. Directors, executive officers and greater than 10% stockholders are required by the rules and
regulations of the SEC to furnish the Company with copies of all reports filed by them in compliance with Section 16(a).
Based
solely on our review of certain reports filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities
Exchange Act of 1934, as amended, the reports required to be filed with respect to transactions in our common stock during the
fiscal year ended September 30, 2015, were timely.
Code
of Ethics
We
have not adopted a Code of Ethics.
Item
11. Executive Compensation
The
following table sets forth compensation information for services rendered by certain of our executive officers in all capacities
during the last two completed fiscal years. The following information includes the dollar value of base salaries and
certain other compensation, if any, whether paid or deferred.
Summary
Compensation Table
Name and Position(s) | |
Year | | |
Salary($) | | |
Bonus | | |
Stock Awards | | |
Option Awards1 | | |
Total Compensation | |
John S. Arnone | |
| 2015 | | |
$ | 19,777 | | |
| | | |
| | | |
$ | 113,314 | | |
$ | 133,091 | |
President and CEO | |
| 2014 | | |
$ | 50,176 | | |
| N/A | | |
| N/A | | |
$ | 219,726 | | |
$ | 269,902 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Anthony F. Dudzinski | |
| 2015 | | |
$ | 23,344 | | |
| | | |
| | | |
$ | 113,314 | | |
$ | 136,648 | |
Chief Operating Officer | |
| 2014 | | |
$ | 41,941 | | |
| N/A | | |
| N/A | | |
$ | 219,726 | | |
$ | 261,667 | |
1This
column represents the aggregate grant-date fair value of the awards computed in accordance with FASB ASC Topic 718. These amounts
represent the accounting value for these awards and do not necessarily correspond to the actual value that may be realized by
the named executive officer. The assumptions used in the calculation of these amounts for the fiscal year ended September 30,
2015 are described in the Notes to our financial statements included in this Annual Report.
Employment
Contracts
The
Company has an Employment Agreement with John Arnone, President and Chief Executive Officer of the Company, which began on October
1, 2012 and expires on October 1, 2020. The Board of Directors determines and approves the annual compensation paid to Mr. Arnone,
which was set at $150,000 in base compensation for Fiscal 2015. During Fiscal 2015, Mr. Arnone was paid $19,777 The Company, however,
has reserved the right in the future to pay unpaid salary in shares of restricted Common Stock.
The
Company has an Employment Agreement with Anthony Dudzinski, Chief Operating Officer of the Company, which began on October 1,
2012 and expires on October 1, 2020. The Board of Directors determines and approves the annual compensation paid to Mr. Dudzinski,
which was set at $150,000 in base compensation for Fiscal 2015. During Fiscal 2015, Mr. Dudzinski was paid $23,344. The
Company, however, has reserved the right in the future to pay any unpaid salary in shares of restricted Common Stock.
We
do not anticipate increasing the annual salaries paid to our officers until we have adequate funds to do so.
Compensation
of Directors
We
do not compensate any of our directors for their services as directors other than stock for their time. However, we do reimburse
our directors for expenses incurred in attending board meetings and issue stock for their time.
Item
12. Security Ownership of Certain Beneficial Owners and Management
The
following table sets forth certain information regarding the beneficial ownership of our Common Stock by: (i) each person who,
to our knowledge, beneficially owns 5% or more of our Common Stock and (ii) each of our directors and officers. Unless otherwise
indicated, each of the stockholders listed below has sole voting and investment power over its shares of Common Stock beneficially
owned.
Name and Address of Beneficial Owner | |
Number of
Shares | | |
Percent
of Class1 | |
Directors and Named Executive Officers 2: | |
| | | |
| | |
John S. Arnone 3 | |
| 24,880,000 | | |
| 71.68 | % |
Anthony Dudzinski 4 | |
| 24,580,000 | | |
| 70.82 | % |
| |
| | | |
| | |
All directors and named executive officers as a group (2 persons) | |
| | | |
| | |
| |
| | | |
| | |
Other 5% or Greater Beneficial Owners | |
| | | |
| | |
ACS Global, Inc. | |
| 21,000,000 | | |
| 60.50 | % |
1Beneficial
ownership is calculated based on 34,705,451 shares of Common Stock issued and outstanding as of September 30, 2015, together
with securities exercisable or convertible into shares of Common Stock within sixty (60) days of the date hereof for each stockholder.
Beneficial ownership is determined in accordance with Rule 13d-3 of the Commission. The number of shares of Common Stock beneficially
owned by a person includes shares of Common Stock issuable upon conversion of securities and subject to options or warrants held
by that person that are currently convertible or exercisable or convertible or exercisable within sixty (60) days of the date
hereof. The shares of Common Stock issuable pursuant to those convertible securities, options or warrants are deemed outstanding
for computing the percentage ownership of the person holding such convertible securities, options or warrants but are not deemed
outstanding for the purposes of computing the percentage ownership of any other person.
2Unless
otherwise specified, the address for the directors and officers is c/o American CryoStem Corporation at 1 Meridian Road, Eatontown,
NJ 07724.
3Mr.
Arnone presently owns 14,250,000 shares of Common Stock of ACS Global and has the right to receive an additional 12,000,000 such
shares upon the conversion of Series C Preferred Stock of ACS Global owned by him. As a result, he beneficially owns 35.8% percent
of the ACS Global Common Stock. Mr. Arnone is also an officer and a director of ACS Global. Consequently, Mr. Arnone is a control
person of ACS Global and may as such be deemed to “beneficially own” the 21,000,000 shares of Common Stock owned by
ACS Global. Mr. Arnone, however, disclaims beneficial ownership of all such shares. Mr. Arnone also holds, 880,000 shares of the
Company’s common shares and 3,000,000 options to purchase the Company’s Common Stock of which 1,000,000 expire on
September 28, 2018 and 1,000,000 expire on September 24, 2019 and 1,000,000 which expire on September 20, 2020.
4Mr.
Dudzinski presently owns 2,020,000 shares of ACS Global Common Stock and has the right to receive an additional 12,000,000 such
shares upon the conversion of ACS Global preferred stock owned by him. As a result, he beneficially owns 19.16% percent of the
ACS Global Common Stock. Mr. Dudzinski is also an officer and a director of ACS Global. Consequently, Mr. Dudzinski is a control
person of ACS Global and may as such be deemed to “beneficially own” the 21,000,000 shares of Common Stock owned by
ACS Global. Mr. Dudzinski, however, disclaims beneficial ownership of all such shares. Mr. Dudzinski also holds 580,000 shares
of the Company’s Common Stock and 3,000,000 options to purchase the Company’s Common Stock of which 580,000 expire
September 4, 2017, 1,000,000 expire on September 28, 2018, 1,000,000 expire on September 24, 2019, and 1,000,000 which expire
on September 20, 2020.
Description
of Securities
We
are authorized to issue 300,000,000 shares of Common Stock, par value $0.001 per share and 50,000,000 shares of preferred stock,
par value $0.0001 per share. As of January 07, 2013, there were 34,705,451 shares of Common Stock and no shares of preferred stock
issued and outstanding.
Outstanding
Equity Awards at Fiscal Year-End
The
following table sets forth information with respect to the outstanding equity awards to our named executive officers during fiscal
2015:
Option Awards | |
| | |
| | |
| | |
| | |
|
Name | |
Number of securities underlying unexercised options (#) Exercisable | | |
Number of securities underlying unexercised options (#) Unexercisable | | |
Equity incentive plan awards: Number of securities underlying unexercised options (#) | | |
Option exercise price ($) | | |
Option expiration date |
John S. Arnone | |
| 1,000,000 | | |
| — | | |
| 1,000,000 | | |
$ | 0.20 | | |
9/24/2018 |
| |
| 1,000,000 | | |
| | | |
| 1,000,000 | | |
$ | 0.25 | | |
9/28/2019 |
| |
| 1,000,000 | | |
| | | |
| 1,000,000 | | |
$ | 0.20 | | |
9/20/2020 |
Anthony Dudzinski | |
| 1,000,000 | | |
| — | | |
| 1,000,000 | | |
$ | 0.20 | | |
9/24/2018 |
| |
| 1,000,000 | | |
| | | |
| 1,000,000 | | |
$ | 0.25 | | |
9/28/2019 |
| |
| 1,000,000 | | |
| | | |
| 1,000,000 | | |
$ | 0.20 | | |
9/20/2020 |
Option
Plans
On
September 18, 2011 our Board of Directors approved the “American CryoStem Corporation Incentive Stock Option Plan”
(the “2011 Plan”). Under the Plan, officers, directors, employees and consultants to the Company may be granted options
to purchase shares of the Company’s common stock, par value $0.001 per share. There are 3,000,000 shares of common stock
reserved for issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”).
The Company issued 2,910,000 of the Options available under the 2011 Plan in Fiscal 2012. To date 1,510,000 options from the 2011
Plan have been exercised and a total of 840,000 remain outstanding at an average weighted exercise price of $0.14.
On
May 1, 2013 our Board of Directors approved the 2013 American CryoStem Corporation Incentive Stock Option Plan (the “2013
Plan”. Under the Plan, officers, directors, employees and consultants to the Company may be granted options to purchase
shares of the Company’s common stock, par value $0.001 per share. There are 5,000,000 shares of common stock reserved for
issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”).
During 2013 the Company granted a total of 3,750,000 at a weighted average price of $0.18 to certain employees, advisory board
members and consultants. To date no Options issued under the plan have been exercised.
On
September 21, 2014 our Board of Directors approved the 2014 American CryoStem Corporation Incentive Stock Option Plan (the “2013
Plan”. Under the Plan, officers, directors, employees and consultants to the Company may be granted options to purchase
shares of the Company’s common stock, par value $0.001 per share. There are 4,000,000 shares of common stock reserved for
issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”).
During 2014 the Company granted a total of 3,516,000 at a weighted average price of $0.21 to certain employees, advisory board
members and consultants. To date no Options issued under the plan have been exercised.
On
September 20, 2015 our Board of Directors approved the 2015 American CryoStem Corporation Incentive Stock Option Plan (the
“2013 Plan”. Under the Plan, officers, directors, employees and consultants to the Company may be granted options
to purchase shares of the Company’s common stock, par value $0.001 per share. There are 4,000,000 shares of common stock
reserved for issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”).
During 2015 the Company granted a total of 3,250,000 at a weighted average price of $0.21 to certain employees, advisory board
members and consultants. To date no Options issued under the plan have been exercised.
Our
current Board of Directors serves as the Committee. The Plan further provides for the Committee to set the terms of any Options
granted at the time of the grant and terminates ten years for its effective date and is subject to final shareholder approval.
On
September 18, 2011, our Board of Directors approved the Annual Bonus Performance Plan for Executive Officers. To promote the success
of our Company by providing to participating executives bonus incentives that qualify as performance-based compensation within
the meaning of Section 162(m) of the Internal Revenue Code of 1986 as amended. The plan provides for the granting of up to an
aggregate amount of bonuses awarded to all Participants of up to 10% of our income before taxes. The plan shall be administered
by a Committee currently consisting of our Board of Directors. No bonuses have been granted under this plan during fiscal 2015.
Item
13. Certain Relationships and Related Transactions
On
April 20, 2011, we acquired, through our wholly owned subsidiary American CryoStem Acquisition Corporation, substantially all
of the assets from, and assumed substantially all of the liabilities of, ACS Global, Inc. (formerly known as American CryoStem
Corporation) a Nevada corporation (“ACS Global”), in exchange for 21,000,000 shares of our Common Stock. At the time
of the acquisition, John Arnone, our Chairman of the Board, CEO and President was a director and the secretary of ACS Global and
Anthony Dudzinski, one of our directors and our Chief Operating Officer, Treasurer and Secretary was a director, president and
secretary of ACS Global. In addition, Mr. Arnone owns 14,250,000 shares of Common Stock of ACS Global and has the right to receive
an additional 12,000,000 such shares upon the conversion of Series C Preferred Stock of ACS Global owned by him and Mr. Dudzinski
owns 2,020,000 shares of ACS Global Common Stock and has the right to receive an additional 12,000,000 such shares upon the conversion
of ACS Global preferred stock owned by him. As a result, assuming the conversion of such preferred stock, Mr. Arnone and Mr. Dudzinski
would have been deemed to be the beneficial owners of approximately 35.8% and 19.1% of the Common Stock of ACS Global, respectively.
Further, Mr. Arnone and Mr. Dudzinski, as control persons of ACS Global may be deemed to beneficially own the 21,000,000 shares
of our Common Stock issued to ACS Global in the acquisition. Each of Mr. Arnone and Mr. Dudzinski disclaim such beneficial ownership.
Mr.
Arnone remains a Director and Secretary of ACS Global and Mr. Dudzinski remains as a Director, President and Treasurer of ACS
Global. Mr. Arnone is also the Chairman and CEO of Personal Cell Sciences, Inc.
Director
Independence
Using
the definition of “independent” using the rules of The Nasdaq Stock Market, we have determined that neither John Arnone
nor Anthony Dudzinski are independent.
Item
14. Principal Accountant Fees and Services
Audit
Fees
The
aggregate fees billed by Donahue Associates, for professional services rendered for the audit of our annual financial statements
for fiscal year ended September 30, 2015 were $13,000 and $10,000 for the fiscal year ended September 2014.
Audit-Related
Fees
There
were no other fees billed by Donahue Associates, LLC for professional services rendered, other than as stated under the captions
Audit Fees.
Tax
Fees
There
were no other fees billed Donahue Associates, LLC for professional services rendered, other than as stated under the captions
Audit Fees.
All
Other Fees
There
were no other fees billed by Donahue Associates, LLC for professional services rendered, other than as stated under the captions
Audit Fees, Audit-Related Fees, and Tax Fees.
PART
IV
Item
15. Exhibits
(a)
SIGNATURES
In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.
|
AMERICAN
CRYOSTEM CORPORATION |
|
|
|
|
|
|
Dated:
January 13, 2016 |
By: |
/s/ John
S, Arnone |
|
|
John
S. Arnone
President,
CEO and Chairman of the Board
|
|
|
|
|
|
|
Dated:
January 13, 2016 |
By: |
/s/
Anthony F. Dudzinski |
|
|
Anthony
F. Dudzinski
COO,
Treasurer, Secretary and Director
|
PART
F/S
INDEX
TO FINANCIAL STATEMENTS
AUDITED
FINANCIAL STATEMENTS
Report
of Independent Registered Public Accounting Firm
The
Shareholders,
American
CryoStem Corporation
We
have audited the accompanying balance sheets of American CryoStem Corporation as of September 30, 2015 and 2014, and the related
statements of operations, stockholders’ equity, and cash flows for each of the two years in the period ended September 30,
2015. These financial statements are the responsibility of the Company’s management. Our responsibility is to express
an opinion on these consolidated financial statements based on our audits.
We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures
in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.
In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of American
CryoStem Corporation as of September 30, 2015 and 2014, and the results of its operations and its cash flows for each of the two
years in the period ended September 30, 2015 in conformity with U.S. generally accepted accounting principles.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 2 to the financial statements, the Company has suffered recurring losses and negative cash flows from operations that
raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters
are also discussed in Note 2. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.
Donahue
Associates LLC
Monmouth
Beach, New Jersey
January
8, 2016
American
CryoStem Corporation
Balance
Sheets
As
of September 30, 2015 and 2014
| |
30-Sep-15 | | |
30-Sep-14 | |
ASSETS | |
| | | |
| | |
| |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash | |
$ | 9,059 | | |
$ | 21,471 | |
Deferred expense | |
| 7,750 | | |
| 54,250 | |
Accounts receivable | |
| 56,513 | | |
| 6,074 | |
Total current assets | |
| 73,322 | | |
| 81,795 | |
| |
| | | |
| | |
Other assets: | |
| | | |
| | |
Other deposits | |
| 2,250 | | |
| 550 | |
Investment in joint venture | |
| 1,000 | | |
| 1,000 | |
Security deposit | |
| 5,950 | | |
| 5,800 | |
Patent- net | |
| 239,807 | | |
| 200,767 | |
Fixed assets- net | |
| 211,314 | | |
| 250,182 | |
| |
| | | |
| | |
Total assets | |
$ | 533,643 | | |
$ | 540,094 | |
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities: | |
| | | |
| | |
Accounts payable & accrued expenses | |
$ | 807,213 | | |
$ | 698,105 | |
Bridge notes payable | |
| 576,000 | | |
| 596,000 | |
Convertible notes payable | |
| 557,000 | | |
| 173,000 | |
Deferred revenues | |
| 56,431 | | |
| 17,768 | |
Capital lease payable | |
| 0 | | |
| 10,898 | |
Total current liabilities | |
$ | 1,996,644 | | |
$ | 1,495,771 | |
| |
| | | |
| | |
Convertible notes payable | |
| 50,000 | | |
| 30,000 | |
Payable to shareholders | |
| 118,347 | | |
| 134,947 | |
| |
| | | |
| | |
Shareholders’ equity: | |
| | | |
| | |
Common stock- $.001 par value, 300,000,000 shares authorized; issued
and outstanding, 32,890,864 shares at September 30, 2014 and 34,705,451 at September 30, 2015 | |
$ | 34,707 | | |
$ | 32,892 | |
Additional paid in capital | |
| 7,876,967 | | |
| 7,010,026 | |
Accumulated deficit | |
| (9,543,022 | ) | |
| (8,163,542 | ) |
Total shareholders’ deficit | |
| (1,631,348 | ) | |
| (1,120,624 | ) |
| |
| | | |
| | |
Total Liabilities & Shareholders’ Deficit | |
$ | 533,643 | | |
$ | 540,094 | |
See
the notes to the financial statements.
American
CryoStem Corporation
Statements
of Operations
For
the Years Ended September 30, 2015 and 2014
| |
30-Sep-15 | | |
30-Sep-14 | |
| |
| | |
| |
Product & Services Revenue | |
$ | 195,378 | | |
$ | 34,599 | |
Royalties | |
| 143,532 | | |
| 86,357 | |
Total Revenues | |
| 338,910 | | |
| 120,956 | |
| |
| | | |
| | |
Cost of Revenues | |
| 99,245 | | |
| 58,059 | |
| |
| | | |
| | |
Gross Profit | |
$ | 239,665 | | |
$ | 62,897 | |
| |
| | | |
| | |
General and administrative expenses: | |
| | | |
| | |
Professional fees | |
$ | 73,405 | | |
$ | 381,214 | |
Laboratory Expenses | |
| 282,519 | | |
| 399,702 | |
Administration | |
| 1,038,385 | | |
| 1,172,003 | |
Total general & administrative expenses | |
| 1,394,309 | | |
| 1,952,919 | |
| |
| | | |
| | |
Net loss from operations | |
($ | 1,154,644 | ) | |
($ | 1,890,022 | ) |
| |
| | | |
| | |
Other income (expenses): | |
| | | |
| | |
Interest expense | |
| (224,836 | ) | |
| (198,127 | ) |
| |
| | | |
| | |
Net loss before provision for income taxes | |
($ | 1,379,480 | ) | |
($ | 2,088,149 | ) |
| |
| | | |
| | |
Provision for income taxes | |
| 0 | | |
| 0 | |
| |
| | | |
| | |
Net loss | |
($ | 1,379,480 | ) | |
($ | 2,088,149 | ) |
| |
| | | |
| | |
Basic & fully diluted net loss per common share: | |
| | | |
| | |
Net loss | |
($ | 0.04 | ) | |
($ | 0.06 | ) |
| |
| | | |
| | |
Weighted average of common shares outstanding: | |
| | | |
| | |
Basic & fully diluted | |
| 33,044,333 | | |
| 32,607,073 | |
See the notes to the financial statements.
American
CryoStem Corporation
Statements
of Cash Flows
For
the Years Ended September 30, 2015 and 2014
| |
30-Sep-15 | | |
30-Sep-14 | |
Operating Activities: | |
| | | |
| | |
Net loss | |
($ | 1,379,480 | ) | |
($ | 2,088,149 | ) |
Adjustments to reconcile net loss items not
requiring the use of cash: | |
| | | |
| | |
Bad debt expense | |
| 16,215 | | |
| 0 | |
Charitable Contributions | |
| 12,500 | | |
| 0 | |
Compensation | |
| 583,025 | | |
| 597,771 | |
Interest expense | |
| 144,324 | | |
| 155,232 | |
Professional fees | |
| 35,407 | | |
| 90,206 | |
Depreciation & amortization expense | |
| 40,864 | | |
| 40,821 | |
Changes in other operating assets and liabilities : | |
| | | |
| | |
Accounts receivable | |
| (66,654 | ) | |
| (4,071 | ) |
Deferred charge | |
| 46,500 | | |
| (54,250 | ) |
Other deposit | |
| (1,700 | ) | |
| (550 | ) |
Deferred revenue | |
| 38,663 | | |
| 17,768 | |
Accounts payable and accrued expenses | |
| 109,108 | | |
| 437,976 | |
Net cash used by operations | |
($ | 421,228 | ) | |
($ | 807,246 | ) |
| |
| | | |
| | |
Investing activities: | |
| | | |
| | |
Patents development | |
($ | 41,036 | ) | |
($ | 38,826 | ) |
Investment in joint venture | |
| 0 | | |
| (1,000 | ) |
Security deposit | |
| (150 | ) | |
| 0 | |
Purchase of lab equipment | |
| 0 | | |
| (7,647 | ) |
Net cash used by investing activities | |
| (41,186 | ) | |
| (47,473 | ) |
| |
| | | |
| | |
Financing activities: | |
| | | |
| | |
Issuance of common shares | |
$ | 55,000 | | |
$ | 0 | |
Issuance of bridge notes | |
| 0 | | |
| 596,000 | |
Issuance of convertible notes | |
| 422,500 | | |
| 164,500 | |
Options exercised | |
| 0 | | |
| 24,500 | |
Payment of capital lease | |
| (10,898 | ) | |
| (20,242 | ) |
Payable to shareholder | |
| (16,600 | ) | |
| (4,500 | ) |
Net cash provided by financing activities | |
| 450,002 | | |
| 760,258 | |
| |
| | | |
| | |
Net increase (decrease) in cash | |
($ | 12,412 | ) | |
($ | 94,461 | ) |
| |
| | | |
| | |
Cash balance at beginning of the fiscal year | |
| 21,471 | | |
| 115,932 | |
| |
| | | |
| | |
Cash balance at end of the fiscal year | |
$ | 9,059 | | |
$ | 21,471 | |
| |
| | | |
| | |
Supplemental disclosures of cash flow information: | |
| | | |
| | |
Interest paid during the fiscal year | |
$ | 3,176 | | |
$ | 2,474 | |
Income taxes paid during the fiscal year | |
$ | 0 | | |
$ | 0 | |
See the notes to the financial statements.
American
CryoStem Corporation
Statements
of Changes in Shareholders’ Equity
For
the Years Ended September 30, 2015 and 2014
| |
Common | | |
Par | | |
Paid in | | |
Retained | | |
Total | |
| |
Shares | | |
Value | | |
Capital | | |
Deficit | | |
Deficit | |
| |
| | |
| | |
| | |
| | |
| |
Balance at September 30, 2013 | |
| 32,285,721 | | |
$ | 32,286 | | |
$ | 5,990,623 | | |
($ | 6,075,393 | ) | |
($ | 52,484 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Exercises of convertible notes and options | |
| 605,143 | | |
| 606 | | |
| 176,194 | | |
| | | |
| 176,800 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of options | |
| | | |
| | | |
| 838,209 | | |
| | | |
| 838,209 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of convertible notes | |
| | | |
| | | |
| 5,000 | | |
| | | |
| 5,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss | |
| | | |
| | | |
| | | |
| (2,088,149 | ) | |
| (2,088,149 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance at September 30, 2014 | |
| 32,890,864 | | |
$ | 32,892 | | |
$ | 7,010,026 | | |
($ | 8,163,542 | ) | |
($ | 1,120,624 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Exercises of convertible notes | |
| 54,286 | | |
| 54 | | |
| 17,446 | | |
| | | |
| 17,500 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Options exercised | |
| 1,460,000 | | |
| 1,460 | | |
| 217,540 | | |
| | | |
| 219,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Shares issued to pay bridge note | |
| 70,000 | | |
| 70 | | |
| 20,930 | | |
| | | |
| 21,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Shares issued to pay interest on bridge note | |
| 4,542 | | |
| 5 | | |
| 1,336 | | |
| | | |
| 1,341 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common shares | |
| 175,759 | | |
| 176 | | |
| 54,824 | | |
| | | |
| 55,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Shares donated to charity | |
| 50,000 | | |
| 50 | | |
| 12,450 | | |
| | | |
| 12,500 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of options | |
| | | |
| | | |
| 399,432 | | |
| | | |
| 399,432 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of convertible notes | |
| | | |
| | | |
| 142,983 | | |
| | | |
| 142,983 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss | |
| | | |
| | | |
| | | |
| (1,379,480 | ) | |
| (1,379,480 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance at September 30, 2015 | |
| 34,705,451 | | |
$ | 34,707 | | |
$ | 7,876,967 | | |
($ | 9,543,022 | ) | |
($ | 1,631,348 | ) |
See the notes to the financial
statements.
American
CryoStem Corporation
Notes
to the Financial Statements
For
the Years Ended September 30, 2015 and 2014
Note
1. Organization of the Company and Significant Accounting Policies
American
CryoStem Corporation (the “Company”) is a publicly held corporation formed on March 13, 2009 in the state of Nevada
as R&A Productions Inc. (R&A)
In
April 2011, R&A purchased substantially all the assets and liabilities of American CryoStem Corporation (ACS), a company formed
in 1987, for 21 million shares of common stock. ACS was deemed to be the accounting acquirer. At the date of the purchase, the
former operations of R&A were discontinued and R&A’s name was changed to ACS.
The
Company is in the business of collecting adipose tissue, processing it to separate the adult stem cells, and preparing such stem
cells for long-term storage. The process allows individuals to preserve their stem cells for future personal use in cellular therapy.
The adipose derived stem cells are prepared and stored in their raw form without manipulation, bio-generation or the addition
of biomarkers or other materials, making them suitable for use in cellular treatments and therapies offered by existing and planned
treatment centers worldwide. Individualized collection and storage of adult stem cells provides personalized medicine solutions
by making the patient’s own preserved stem cells available for future cellular therapies.
The
Company has devoted a significant amount of its time and resources to develop its technologies and intellectual property. These
efforts have resulted in the development of cell lines, cell culture medium and other laboratory products which the Company believes
are suitable for licensing and distribution by third parties. Additionally the Company has initiated a licensing program to license
its technologies to laboratories currently processing other types of biologic materials including cord blood and general blood
banks. The Company closed its first licensing agreement in 2014 and closed an additional territory in fiscal 2015 intends to pursue
additional licensing partners in the future. Under the terms of the licensing agreements, Licensees purchase certain consumables
from the Company including the Company’s CELLECT collection kits and ACSelerate cellular mediums. The Company has also entered
into its first private label arrangement in 2015, distributing its CELLECT kits and performing its ATGRAFT and ATCELL processing
under a contract executed in Fiscal 2015.
Use
of Estimates - The preparation of the financial statements in conformity with United States generally accepted accounting
principles (“GAAP”) uniformly applied requires management to make reasonable estimates and assumptions that affect
the reported amounts of the assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts
of revenues and expenses at the date of the financial statements and for the period they include. Actual results may differ from
these estimates.
Cash
- For the purpose of calculating changes in cash flows, cash includes all cash balances and highly liquid short-term investments
with an original maturity of three months or less.
Revenue
Recognition – The Company recognizes tissue processing revenue from the processing of adipose tissue into usable stem
cells once all the procedures have been performed and the client sample has been stored in the Company’ cryogenic storage
tank. Storage revenues for stored client samples are recognized on an annual basis on the anniversary date of the storage. Royalties
from the licensing of the Company’s assets are recognized when earned and collection of the royalty is reasonable assured.
Revenue derived from the sales of collection kits and medium products to Licensees is recognized upon shipment of the products
to the licensee.
Long
Lived Assets - The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash
flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount.
Fixed
Assets – Fixed assets are stated at cost. Depreciation expense is computed using the straight-line method over
the estimated useful life of the assets, which is estimated as follows:
|
Office
equipment |
5
years |
|
|
Lab equipment
& furniture |
7 years |
|
|
Lab software |
5 years |
|
Income
taxes - The Company accounts for income taxes in accordance with generally accepted accounting principles which require an
asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities
are computed annually for differences between financial statement and income tax bases of assets and liabilities that will result
in taxable income or deductible expenses in the future based on enacted tax laws and rates applicable to the periods in which
the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred
tax assets and liabilities to the amount expected to be realized. Income tax expense is the tax payable or refundable for the
period adjusted for the change during the period in deferred tax assets and liabilities.
The
Company follows the accounting requirements associated with uncertainty in income taxes using the provisions of Financial Accounting
Standards Board (FASB) ASC 740, Income Taxes. Using that guidance, tax positions initially need to be recognized in the financial
statements when it is more likely than not the positions will be sustained upon examination by the tax authorities. It also provides
guidance for derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
As of September 30, 2015 and September 30, 2014, the Company has no uncertain tax positions that qualify for either recognition
or disclosure in the financial statements. All tax returns from fiscal years 2011 to 2015 are subject to IRS audit.
Recently
Issued Accounting Pronouncements- There are no recently issued accounting pronouncements that have a material impact on the
Company’s financial statements.
Note
2. Going Concern
The
accompanying financial statements have been presented in accordance with generally accepted accounting principles in the U.S.,
which assume the continuity of the Company as a going concern. However, the Company has incurred significant losses since its
inception and has no material revenues to date and continues to rely on financing and the issuance of debt and equity to raise
capital to fund its business operations. Management’s plans with regard to this matter are as follows:
The
Company plans to continue to fund its operations through capital fundraising activities through the sale of its debt and equity
securities in fiscal 2016 until it generates sufficient revenue to support its operations.
Note
3. Loss per Share
The
Company applies ASC 260, “Earnings per Share” to calculate loss per share. In accordance with ASC 260, basic
and fully diluted net loss per share has been computed based on the weighted average of common shares outstanding during the years.
The dilutive effects of the convertible notes and the options outstanding are not included in the calculation of loss per share
since their inclusion would be anti-dilutive.
Net
loss per share is computed as follows:
| |
30-Sep-15 | | |
30-Sep-14 | |
| |
| | |
| |
Net loss | |
($ | 1,379,480 | ) | |
($ | 2,088,149 | ) |
| |
| | | |
| | |
Weighted average shares outstanding | |
| 33,044,333 | | |
| 32,607,073 | |
| |
| | | |
| | |
Basic & fully diluted net loss per common share: | |
| | | |
| | |
Net gain (loss) | |
($ | 0.04 | ) | |
($ | 0.06 | ) |
Note
4. Fixed Assets
The
fixed assets owned by the Company are comprised as follows.
| |
30-Sep-15 | | |
30-Sep-14 | |
| |
| | |
| |
Office equipment | |
$ | 26,637 | | |
$ | 26,637 | |
Lab furniture | |
| 642 | | |
| 642 | |
Office furniture | |
| 999 | | |
| 999 | |
Lab equipment | |
| 254,054 | | |
| 254,054 | |
Lab software | |
| 123,000 | | |
| 123,000 | |
Accumulated depreciation | |
| (194,018 | ) | |
| (155,150 | ) |
| |
| | | |
| | |
Fixed assets- net | |
$ | 211,314 | | |
$ | 250,182 | |
Lab
equipment includes $88,000 of leased equipment. Depreciation expense on this leased asset for 2015 and 2014 was $12,521 and $12,571,
respectively.
Note
5. Patent & Patents Filings
The
patent and patents development are recorded at cost and are being amortized on a straight line basis over a period of seventeen
years. The following is a description of the Company’s patent assets.
On
August 2, 2011, the Company was awarded U.S. Patent No. US 7,989,205 B2, titled Cell Culture Media, Kits, and Methods of Use.
The Patent is for cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin
suitable for both research and clinical applications. The Company filed and maintains a continuation (U.S. Serial No. 13/194,900)
with additional claims pending
The
Company has filed the following additional patents to extend its intellectual property to encompass additional aspects of the
Company’s platform processing technologies. To date the following additional patent filings have been made.
A
business method for Collection, Cryogenic Storage and Distribution of a Biologic Sample Material US Serial No. 13/702,304 filed
June 6, 2011with a priority date of June 6, 2010
Systems
and Methods for the Digestion of Adipose Tissue Samples Obtained from a Client for Cryopreservation U.S. Serial No. 13/646,647
filed October 5, 2012 with a priority date of October 6, 2011
Compositions
and Methods for Collecting, Washing, Cryopreserving, Recovering and Return of Lipoaspirates to Physician for Autologous Adipose
Transfer Procedures PCT/US13/44621 filed June 6, 2013 with a priority date of June 7, 2013
Stem
Cell Based Therapuetic Devices and Methods U.S. Serial No. 14/196,616 filed March 4, 2014 with a priority dated of March 10, 2013
Autologous
Serum for Transport of Isolated Stromal Vascular Fraction or Adipose Derived Stem Cells US Serial No. 14,250,338 filed in 2014
with a priority date of April 11, 2013
Cell
Culture Media, Kits and Methods of Use, US Serial No. 13/1-94/900 continuation of US Serial No. 11/542,863
Human
Serum for Cell Culture Medium for Clinical Growth of Human Adipose Stromal Cells, PCT/US/68350 Filed December 31, 2015 with a
priority date of December 31, 2014
Note
6. Debt
As
of September 30, 2015, the Company had $607,000 of convertible notes outstanding. Convertible notes of $159,500 came due on September
30, 2014. The Company is currently in negotiations with the holders of these notes to convert their notes or to extend their maturity
dates. These notes are convertible into common stock at $0.35 per share. Convertible notes of $447,500 are due at the end of fiscal
years 2016 and 2017 and are exercisable into common stock at $0.30 per share.
During
fiscal year 2014, the company issued “bridge notes” and received proceeds of $576,000, which were due in fiscal year
2015. The notes are currently in default and due on demand. Holders of the notes received options to purchase 576,000 shares of
common stock at $0.05 per share. The notes are unsecured.
The
following table describes the Company’s debt outstanding at September 30, 2015.
Debt | |
Carrying Value | | |
Fair Value | | |
Maturity | |
Rate | |
|
| |
| | |
| | |
| |
| |
|
Convertible notes | |
$ | 159,500 | | |
$ | 159,500 | | |
Demand | |
8.00% | |
In default |
| |
| | | |
| | | |
| |
| | |
|
Convertible notes | |
$ | 397,500 | | |
$ | 397,500 | | |
Fiscal 2016 | |
8.00% | |
|
| |
| | | |
| | | |
| |
| | |
|
Convertible notes | |
$ | 50,000 | | |
$ | 53,000 | | |
Fiscal 2017 | |
8.00% | |
|
| |
| | | |
| | | |
| |
| | |
|
Bridge notes | |
$ | 576,000 | | |
$ | 576,000 | | |
Demand | |
8.00% | |
In default |
| |
| | | |
| | | |
| |
| | |
|
Due to shareholders | |
$ | 118,347 | | |
$ | 118,347 | | |
Demand | |
0.00% | |
|
Note
7. Administration Expense
A
detail of administrative expenses in the statements of operations is as follows.
| |
30-Sep-15 | | |
30-Sep-14 | |
| |
| | |
| |
Advertising & promotion | |
$ | 57,383 | | |
$ | 110,421 | |
Automobile | |
| 2,505 | | |
| 5,500 | |
Bad debt expense | |
| 16,215 | | |
| 0 | |
Bank fees | |
| 824 | | |
| 567 | |
Business meetings | |
| 7,054 | | |
| 7,991 | |
Charitable Contributions | |
| 12,500 | | |
| 65 | |
Consulting | |
| 191,510 | | |
| 331,943 | |
Depreciation & amortization | |
| 40,863 | | |
| 40,821 | |
Dues & subscriptions | |
| 675 | | |
| 3,825 | |
Insurance | |
| 2,290 | | |
| 4,235 | |
Travel & meals | |
| 45,660 | | |
| 28,313 | |
General Office Expenses | |
| 26,181 | | |
| 39,480 | |
Compensation (Options) | |
| 568,425 | | |
| 539,713 | |
Rent | |
| 31,800 | | |
| 31,350 | |
Postage | |
| 14,890 | | |
| 14,662 | |
Telecommunications | |
| 10,342 | | |
| 9,181 | |
Utilities | |
| 4,184 | | |
| 2,129 | |
Web site maintenance | |
| 5,084 | | |
| 1,807 | |
| |
| | | |
| | |
Total | |
$ | 1,038,385 | | |
$ | 1,172,003 | |
Note
8. Common Stock Issuances
During
fiscal year 2014, option holders exercised 170,000 options and the Company issued 170,000 shares of common stock and received
proceeds of $24,500.
During
fiscal year 2014, holders of convertible notes converted $152,300 of convertible notes and the Company issued 435,143 shares of
common stock.
During
fiscal year 2015, debenture holders converted $17,500 of convertible notes into 54,286 shares of common stock.
During
fiscal year 2015, officers of the Company exercised 1,460,000 options at $0.01 and received 1,460,000 shares.
During
fiscal year 2015, the Company issued 70,000 shares of common stock to pay $21,000 of the bridge loan discussed in Note 6. As part
of this payment, the Company issued 4,542 shares to pay interest due on the bridge loan.
During
fiscal year 2015, the Company issued 175,759 shares of common stock and received proceeds of $55,000.
During
fiscal year 2015, the Company issued 50,000 shares of common stock to a charitable organization and recognized and expense of
$12.500.
Note
9. Option Issuances
The
Company applies ASC 718, “Accounting for Stock-Based Compensation” to account for its option issues. Accordingly,
all options granted are recorded at fair value using a generally accepted option pricing model at the date of the grant. The Company
uses the Black-Sholes option pricing model to measure the fair values of its option grants. For purposes of determining the
option values at issuance, the fair value of each option granted is measured at the date of the grant by the option pricing model
with the following assumptions:
| |
2015 | | |
2014 | |
| |
| | |
| |
Dividend yield | |
| 0.00 | % | |
| 0.00 | % |
Risk free interest rate | |
| 0.25 | % | |
| 0.25 | % |
Volatility | |
| 26.37 | % | |
| 48.39 | % |
The
fair values generated by option pricing model may not be indicative of the future values, if any, that may be received by the
option holder.
During
fiscal year 2015, the Company issued 3,525,000 options to employees. As a result, the Company recorded labor expense of $399,432,
in its statement of operations.
The
following is a summary of common stock options outstanding at September 30, 2015:
| |
Amount | | |
Wgtd Avg Exercise Price | | |
Wgtd Years to Maturity | |
| |
| | |
| | |
| |
Outstanding at September 30, 2013 | |
| 6,910,000 | | |
$ | 0.18 | | |
| 4.16 | |
| |
| | | |
| | | |
| | |
Issues | |
| 3,816,000 | | |
| | | |
| | |
Exercises | |
| (170,000 | ) | |
| | | |
| | |
Expires | |
| 0 | | |
| | | |
| | |
| |
| | | |
| | | |
| | |
Outstanding at September 30, 2014 | |
| 10,556,000 | | |
$ | 0.21 | | |
| 3.74 | |
| |
| | | |
| | | |
| | |
Issues | |
| 3,525,000 | | |
| | | |
| | |
Exercises | |
| (1,460,000 | ) | |
| | | |
| | |
Expires | |
| (300,000 | ) | |
| | | |
| | |
| |
| | | |
| | | |
| | |
Outstanding at September 30, 2015 | |
| 12,321,000 | | |
$ | 0.21 | | |
| 3.41 | |
Note
10. Fair Values of Financial Instruments
Fair
Value Measurements under generally accepted accounting principles clarifies the principle that fair value should be based
on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that
prioritizes the information used to develop those assumptions. Under the standard, fair value measurements are separately disclosed
by level within the fair value hierarchy as follows.
Level
1 - Quoted prices in active markets for identical assets or liabilities.
Level
2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets
with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant
inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full
term of the assets or liabilities.
Level
3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
To
the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination
of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels
of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which
the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value
measurement.
Cash,
accounts receivable, deferred expense, other deposit, security deposit, accounts payable and accrued expenses, capital lease payable,
bridge notes payable, deferred revenue, payable to shareholder, and advances payable to shareholder in the balance sheet are estimated
to approximate fair market value at September 30, 2015 and September 30, 2014 because of their short term nature.
Note
11. Commitments & Contingencies
Operating
Leases - The Company leases laboratory facilities at the Burlington County College Science Incubator in Burlington, New Jersey.
The lease is on a “month to month” basis and rents for $2,700 per month. Burlington County College has terminated
the lease as of January 15, 2016. The Company has fulfilled its lease obligation to the college.
The
Company plans to execute a new lease for laboratory facilities in Princeton, New Jersey and plans to move into the new
facilities with minimal interruption to laboratory operations and customer service.
The
Company leases office facilities on Meridian Road in Eatontown, New Jersey. The lease is on a “month to month” basis
and rents for $2,650 per month.
The
Company is not party to any litigation against it and is not aware of any litigation contemplated against it as of September 30,
2015.
Note
12. Concentrations of Credit
The
Company largely relies on the efforts of its Chief Operating Officer and its Chief Executive Officer. A withdrawal of the efforts
of these individuals would have a material adverse affect on the Company’s ability to continue as a going concern.
Note
13. Joint Venture
During
fiscal year 2014, the Company invested $1,000 in a joint venture. The joint venture is called Autogenesis Corporation and was
incorporated in the state of Florida. The Company and its two chief executives own 50% of Autogenesis. Autogenesis was formed
for the purpose of developing a wound healing protocol. The Company has no further obligations to Autogenesis and the joint venture
will be responsible for its own funding.
Note
14. Related Party Transactions
The
other party to the joint venture discussed in Note 13 is controlled by a member of the Company’s scientific advisory board.
At
September 30, 2015, the company was indebted to its majority shareholder for advances related to the R&A transaction and additional
amounts to the Company’s Chairman and Chief Executive for net advances to the Company of $118,347. The advances are due
on demand, are unsecured, and carry no interest rate.
Note
15. Subsequent Events
The
Company has made a review of material subsequent events from September 30, 2015 through the date of this report and found no material
subsequent events reportable during this period.
EXHIBIT
31.1
Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
I, John Arnone, certify that:
1. I have reviewed this annual report on Form 10-K of American CryoStem Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: January 13, 2016
|
/s/ John Arnone
|
|
|
John Arnone,
Principal Executive Officer
|
|
EXHIBIT
31.2
Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
I, Anthony Dudzinski, certify that:
1. I have reviewed this annual report on Form 10-K of American CryoStem Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: January 13, 2016
|
/s/ Anthony Dudzinski
|
|
|
Anthony Dudzinski,
Principal Financial Officer
|
|
EXHIBIT
32.1
CERTIFICATION
PURSUANT TO
18
U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO SECTION 906 OF
THE
SARBANES-OXLEY ACT OF 2002
In
connection with this Annual Report of American CryoStem Corporation (the “Company”), on Form 10-K for the
year ended September 30, 2015, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, John
Arnone, Principal Executive Officer of the registrant and Anthony Dudzinski, Principal Financial Officer of the registrant,
certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley
Act of 2002, that:
| (1) | Such Annual Report on Form 10-K for the year ended
September 30, 2015 fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and |
| (2) | The information contained in such Annual Report on Form
10-K for the year ended September 30, 2015 fairly presents, in all material respects, the financial condition and
results of
operations of the Company. |
|
|
|
|
Dated: January
13, 2016 |
By: |
/s/
John Arnone |
|
|
|
John
Arnone |
|
|
|
Principal
Executive Officer
American
CryoStem Corporation |
|
|
|
|
|
Dated:
January 13, 2016 |
By: |
/s/
Anthony Dudzinski |
|
|
|
Anthony
Dudzinski |
|
|
|
Principal
Financial Officer
American
CryoStem Corporation |
|
v3.3.1.900
X |
- DefinitionIf the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionState aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
+ Details
Name: |
dei_EntityPublicFloat |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
+ Details
Name: |
dei_EntityVoluntaryFilers |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
+ Details
Name: |
dei_EntityWellKnownSeasonedIssuer |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Balance Sheets - USD ($)
|
Sep. 30, 2015 |
Sep. 30, 2014 |
Current assets: |
|
|
Cash |
$ 9,059
|
$ 21,471
|
Deferred Expense |
7,750
|
54,250
|
Accounts receivable |
56,513
|
6,074
|
Total current assets |
73,322
|
81,795
|
Other assets: |
|
|
Other deposit |
2,250
|
550
|
Investment in joint venture |
1,000
|
1,000
|
Security deposit |
5,950
|
5,800
|
Patent- net |
239,807
|
200,767
|
Fixed assets- net |
211,314
|
250,182
|
Total Assets |
533,643
|
540,094
|
Current liabilities: |
|
|
Accounts payable & accrued expenses |
807,213
|
698,105
|
Bridge notes payable |
576,000
|
596,000
|
Convertible notes payable |
557,000
|
173,000
|
Deferred revenues |
56,431
|
17,768
|
Capital Lease Payable |
0
|
10,898
|
Total current liabilities |
1,996,644
|
1,495,771
|
Convertible notes payable |
50,000
|
30,000
|
Payable to Shareholders |
118,347
|
134,947
|
Shareholders' equity: |
|
|
Common stock- $.001 par value, 300,000,000 shares authorized; issued and outstanding, 32,890,864 shares at September 30, 2014 and 34,705,451 at September 30, 2015 |
34,707
|
32,892
|
Additional paid in capital |
7,876,967
|
7,010,026
|
Accumulated deficit |
(9,543,022)
|
(8,163,542)
|
Total shareholders' deficit |
(1,631,348)
|
(1,120,624)
|
Total Liabilities & Shareholders' Deficit |
$ 533,643
|
$ 540,094
|
X |
- Definition
+ References
+ Details
Name: |
fil_InvestmentInJointVenture |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of net assets (liabilities).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09.6,7) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606914-122999
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35686370&loc=SL35686385-199418
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05.4) -URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604008-122996
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 09 -Paragraph 19 -Article 6
+ Details
Name: |
us-gaap_AssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5
+ Details
Name: |
us-gaap_CapitalLeaseObligationsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_ConvertibleLongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_ConvertibleNotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DeferredCostsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A
+ Details
Name: |
us-gaap_DeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of receivables owed to an entity that is affiliated with the reporting entity by means of direct or indirect ownership, which are usually due after one year (or one business cycle, if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.23) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 12 -Subparagraph 3 -Article 6
+ Details
Name: |
us-gaap_DueToAffiliateNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionGross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedPatentsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherAssetsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8,17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_SecurityDeposit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Balance Sheets (Parenthetical) - $ / shares
|
Sep. 30, 2015 |
Sep. 30, 2014 |
Assets [Abstract] |
|
|
Common Stock, Par Value |
$ 0.001
|
$ 0.001
|
Common stock, authorized |
300,000,000
|
300,000,000
|
Common Stock, shares issued |
34,705,451
|
32,890,864
|
X |
- References
+ Details
Name: |
us-gaap_AssetsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.3.1.900
Statements of Operations - USD ($)
|
12 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Revenues [Abstract] |
|
|
Product & Services Revenue |
$ 195,378
|
$ 34,599
|
Royalties |
143,532
|
86,357
|
Total revenues |
338,910
|
120,956
|
Cost of Revenues |
99,245
|
58,059
|
Gross Profit |
239,665
|
62,897
|
General and administrative expenses: |
|
|
Professional Fees |
73,405
|
381,214
|
Laboratory Expenses |
282,519
|
399,702
|
Administration |
1,038,385
|
1,172,003
|
Total general & administrative expenses |
1,394,309
|
1,952,919
|
Net Loss from Operations |
(1,154,644)
|
(1,890,022)
|
Other income (expenses): |
|
|
Interest expense |
(224,836)
|
(198,127)
|
Net loss before provision for income taxes |
(1,379,480)
|
(2,088,149)
|
Provision for income taxes |
0
|
0
|
Net Loss |
$ (1,379,480)
|
$ (2,088,149)
|
Basic & fully diluted net loss per common share: |
|
|
Net loss |
$ (.04)
|
$ (0.06)
|
Weighted average of common shares outstanding: |
|
|
Basic & fully diluted |
33,044,333
|
32,607,073
|
X |
- References
+ Details
Name: |
fil_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_CostOfRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDilutedAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ References
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe sum of expenses not otherwise specified in the taxonomy for managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OtherGeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRevenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OtherSalesRevenueNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849
+ Details
Name: |
us-gaap_ProfessionalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_RevenuesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_RoyaltyRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionTotal revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_SalesRevenueNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
+ Details
Name: |
us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Statements of Cash Flows - USD ($)
|
12 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Operating Activities: |
|
|
Net loss |
$ (1,379,480)
|
$ (2,088,149)
|
Adjustments to reconcile net loss items not requiring the use of cash: |
|
|
Bad debt expense |
16,215
|
0
|
Charitable Contributions |
12,500
|
0
|
Compensation |
583,025
|
597,771
|
Interest expense |
144,324
|
155,232
|
Professional fees |
35,407
|
90,206
|
Depreciation & amortization expense |
40,864
|
40,821
|
Changes in other operating assets and liabilities: |
|
|
Accounts Receivable |
(66,654)
|
(4,071)
|
Deferred charge |
46,500
|
(54,250)
|
Other deposit |
(1,700)
|
(550)
|
Deferred Revenue |
38,663
|
17,768
|
Accounts Payable and accrued expenses |
109,108
|
437,976
|
Net cash used by operations |
(421,228)
|
(807,246)
|
Investing activities: |
|
|
Patents development |
(41,036)
|
(38,826)
|
Investment in joint venture |
0
|
(1,000)
|
Security deposit |
(150)
|
0
|
Purchase of lab equipment |
0
|
(7,647)
|
Net cash used by investing activities |
(41,186)
|
(47,473)
|
Financing activities: |
|
|
Issuance of common shares |
55,000
|
0
|
Issuance of bridge notes |
0
|
596,000
|
Issuance of convertible notes |
422,500
|
164,500
|
Options exercised |
0
|
24,500
|
Payment of capital lease |
(10,898)
|
(20,242)
|
Payable to shareholder |
(16,600)
|
(4,500)
|
Net cash provided by financing activities |
450,002
|
760,258
|
Net increase (decrease) in cash |
(12,412)
|
(94,461)
|
Cash balance at beginning of the fiscal year |
21,471
|
115,932
|
Cash balance at ending of the fiscal year |
9,059
|
21,471
|
Supplemental disclosures of cash flow information: |
|
|
Interest paid during the fiscal year |
3,176
|
2,474
|
Income taxes paid during the fiscal year |
$ 0
|
$ 0
|
X |
- References
+ Details
Name: |
fil_IncreaseDecreaseCharitableContributions |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
fil_IncreaseDecreaseProfessionalFees |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInDeferredCharges |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInDeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in intangible assets (for example patents and licenses).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInInterestPayableNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in security deposits.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInSecurityDeposits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of cash paid for interest during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details
Name: |
us-gaap_InterestPaid |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquireInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_PaymentsToMinorityShareholders |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (j) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_ProceedsFromStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.5) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
+ Details
Name: |
us-gaap_RepaymentsOfLongTermCapitalLeaseObligations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionExpenditures for salaries other than officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_SalariesAndWages |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.3.1.900
Statements of Changes in Shareholder's Equity - USD ($)
|
Common Stock |
Additional Paid-In Capital |
Retained Earnings / Accumulated Deficit |
Total |
Balance at Sep. 30, 2013 |
$ 32,286
|
$ 5,990,623
|
$ (6,075,393)
|
$ (52,484)
|
Balance (in Shares) at Sep. 30, 2013 |
32,285,721
|
|
|
|
Exercises of convertible notes and options |
$ 606
|
176,194
|
|
$ 176,800
|
Exercises of convertible notes and options (in shares) |
605,143
|
|
|
435,143
|
Issuance of common shares |
|
|
|
$ 0
|
Issuance of options |
|
838,209
|
|
838,209
|
Issuance of convertible notes |
|
5,000
|
|
5,000
|
Net loss |
|
|
(2,088,149)
|
(2,088,149)
|
Balance at Sep. 30, 2014 |
$ 32,892
|
7,010,026
|
(8,163,542)
|
(1,120,624)
|
Balance (in Shares) at Sep. 30, 2014 |
32,890,864
|
|
|
|
Exercises of convertible notes and options |
$ 54
|
17,446
|
|
$ 17,500
|
Exercises of convertible notes and options (in shares) |
54,286
|
|
|
54,286
|
Options exercised |
$ 1,460
|
217,540
|
|
$ 219,000
|
Options exercised (in shares) |
1,460,000
|
|
|
1,460,000
|
Shares issued to pay bridge note |
$ 70
|
20,930
|
|
$ 21,000
|
Shares issued to pay bridge note (in shares) |
70,000
|
|
|
70,000
|
Shares issued to pay interest on bridge note |
$ 5
|
1,336
|
|
$ 1,341
|
Shares issued to pay interest on bridge note (in shares) |
4,542
|
|
|
|
Issuance of common shares |
$ 176
|
54,824
|
|
55,000
|
Issuance of common shares (in shares) |
175,759
|
|
|
|
Shares donated to charity |
$ 50
|
12,450
|
|
12,500
|
Shares donated to charity (in shares) |
50,000
|
|
|
|
Issuance of options |
|
399,432
|
|
399,432
|
Issuance of convertible notes |
|
142,983
|
|
142,983
|
Net loss |
|
|
(1,379,480)
|
(1,379,480)
|
Balance at Sep. 30, 2015 |
$ 34,707
|
$ 7,876,967
|
$ (9,543,022)
|
$ (1,631,348)
|
Balance (in Shares) at Sep. 30, 2015 |
34,705,451
|
|
|
|
X |
- DefinitionRepresents the amount recognized in additional paid in capital due to issuance of convertible notes during the period.
+ References
+ Details
Name: |
fil_AdjustmentsToAdditionalPaidInCapitalConvertibleNotesIssued |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_IssuanceOfCommonShares |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesDonatedToCharity |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesDonatedToCharityShares |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesIssuedToPayBridgeNote |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesIssuedToPayBridgeNoteShares |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesIssuedToPayInterestOnBridgeNote |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesIssuedToPayInterestOnBridgeNoteShares |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued as a result of the exercise of stock options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
1. Organization of the Company and Significant Accounting Policies
|
12 Months Ended |
Sep. 30, 2015 |
Organization of the Company and Significant Accounting Policies |
|
Organization of the Company and Significant Accounting Policies |
American CryoStem Corporation (the Company)
is a publicly held corporation formed on March 13, 2009 in the state of Nevada as R&A Productions Inc. (R&A)
In April 2011, R&A purchased substantially all the assets
and liabilities of American CryoStem Corporation (ACS), a company formed in 1987, for 21 million shares of common stock. ACS was
deemed to be the accounting acquirer. At the date of the purchase, the former operations of R&A were discontinued and R&As
name was changed to ACS.
The Company is in the business of collecting adipose tissue,
processing it to separate the adult stem cells, and preparing such stem cells for long-term storage. The process allows individuals
to preserve their stem cells for future personal use in cellular therapy. The adipose derived stem cells are prepared and stored
in their raw form without manipulation, bio-generation or the addition of biomarkers or other materials, making them suitable for
use in cellular treatments and therapies offered by existing and planned treatment centers worldwide. Individualized collection
and storage of adult stem cells provides personalized medicine solutions by making the patients own preserved stem cells
available for future cellular therapies.
The Company has devoted a significant amount of its time and
resources to develop its technologies and intellectual property. These efforts have resulted in the development of cell lines,
cell culture medium and other laboratory products which the Company believes are suitable for licensing and distribution by third
parties. Additionally the Company has initiated a licensing program to license its technologies to laboratories currently processing
other types of biologic materials including cord blood and general blood banks. The Company closed its first licensing agreement
in 2014 and closed an additional territory in fiscal 2015 intends to pursue additional licensing partners in the future. Under
the terms of the licensing agreements, Licensees purchase certain consumables from the Company including the Companys CELLECT
collection kits and ACSelerate cellular mediums. The Company has also entered into its first private label arrangement in 2015,
distributing its CELLECT kits and performing its ATGRAFT and ATCELL processing under a contract executed in Fiscal 2015.
Use of Estimates - The preparation of the financial
statements in conformity with United States generally accepted accounting principles (GAAP) uniformly applied requires
management to make reasonable estimates and assumptions that affect the reported amounts of the assets and liabilities and disclosure
of contingent assets and liabilities and the reported amounts of revenues and expenses at the date of the financial statements
and for the period they include. Actual results may differ from these estimates.
Cash - For the purpose of calculating changes in cash flows,
cash includes all cash balances and highly liquid short-term investments with an original maturity of three months or less.
Revenue Recognition The Company recognizes
tissue processing revenue from the processing of adipose tissue into usable stem cells once all the procedures have been performed
and the client sample has been stored in the Company cryogenic storage tank. Storage revenues for stored client samples
are recognized on an annual basis on the anniversary date of the storage. Royalties from the licensing of the Companys assets
are recognized when earned and collection of the royalty is reasonable assured. Revenue derived from the sales of collection kits
and medium products to Licensees is recognized upon shipment of the products to the licensee.
Long Lived Assets - The Company reviews for the impairment
of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual
disposition is less than its carrying amount.
Fixed Assets Fixed assets are stated
at cost. Depreciation expense is computed using the straight-line method over the estimated useful life of the assets, which is
estimated as follows:
|
Office equipment |
5 years |
|
|
Lab equipment & furniture |
7 years |
|
|
Lab software |
5 years |
|
Income taxes - The Company accounts for income taxes
in accordance with generally accepted accounting principles which require an asset and liability approach to financial accounting
and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for differences between financial
statement and income tax bases of assets and liabilities that will result in taxable income or deductible expenses in the future
based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation
allowances are established when necessary to reduce deferred tax assets and liabilities to the amount expected to be realized.
Income tax expense is the tax payable or refundable for the period adjusted for the change during the period in deferred tax assets
and liabilities.
The Company follows the accounting requirements
associated with uncertainty in income taxes using the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income
Taxes. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than
not the positions will be sustained upon examination by the tax authorities. It also provides guidance for derecognition, classification,
interest and penalties, accounting in interim periods, disclosure and transition. As of September 30, 2015 and September 30, 2014,
the Company has no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. All tax
returns from fiscal years 2011 to 2015 are subject to IRS audit.
Recently Issued Accounting Pronouncements- There are no recently
issued accounting pronouncements that have a material impact on the Companys financial statements.
|
X |
- References
+ Details
Name: |
fil_AccountingPoliciesAbstract1 |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.
+ References
+ Details
Name: |
us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
2. Going Concern
|
12 Months Ended |
Sep. 30, 2015 |
Going Concern |
|
Going Concern |
The accompanying financial statements have been presented
in accordance with generally accepted accounting principles in the U.S., which assume the continuity of the Company as a going
concern. However, the Company has incurred significant losses since its inception and has no material revenues to date and continues
to rely on financing and the issuance of debt and equity to raise capital to fund its business operations. Managements plans
with regard to this matter are as follows:
The Company plans to continue to fund its operations through
capital fundraising activities through the sale of its debt and equity securities in fiscal 2016 until it generates sufficient
revenue to support its operations.
|
X |
- References
+ Details
Name: |
fil_GoingConcernAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 40 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=51888302&loc=SL51888449-203568
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 40 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51888302&loc=SL51888443-203568
+ Details
Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
3. Loss per Share
|
12 Months Ended |
Sep. 30, 2015 |
Loss per Share |
|
Loss per Share |
The Company applies ASC 260, Earnings per Share
to calculate loss per share. In accordance with ASC 260, basic and fully diluted net loss per share has been computed based
on the weighted average of common shares outstanding during the years. The dilutive effects of the convertible notes and the options
outstanding are not included in the calculation of loss per share since their inclusion would be anti-dilutive.
Net loss per share is computed as follows:
|
|
30-Sep-15 |
|
|
30-Sep-14 |
|
|
|
|
|
|
|
|
Net loss |
|
($ |
1,379,480 |
) |
|
($ |
2,088,149 |
) |
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding |
|
|
33,044,333 |
|
|
|
32,607,073 |
|
|
|
|
|
|
|
|
|
|
Basic & fully diluted net loss per common share: |
|
|
|
|
|
|
|
|
Net gain (loss) |
|
($ |
0.04 |
) |
|
($ |
0.06 |
) |
|
X |
- References
+ Details
Name: |
fil_EarningsPerShareAbstract1 |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for earnings per share.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_EarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
4. Fixed Assets
|
12 Months Ended |
Sep. 30, 2015 |
Fixed Assets |
|
Fixed Assets |
The fixed assets owned by the Company are comprised as follows.
|
|
30-Sep-15 |
|
|
30-Sep-14 |
|
|
|
|
|
|
|
|
Office equipment |
|
$ |
26,637 |
|
|
$ |
26,637 |
|
Lab furniture |
|
|
642 |
|
|
|
642 |
|
Office furniture |
|
|
999 |
|
|
|
999 |
|
Lab equipment |
|
|
254,054 |
|
|
|
254,054 |
|
Lab software |
|
|
123,000 |
|
|
|
123,000 |
|
Accumulated depreciation |
|
|
(194,018 |
) |
|
|
(155,150 |
) |
|
|
|
|
|
|
|
|
|
Fixed assets- net |
|
$ |
211,314 |
|
|
$ |
250,182 |
|
Lab equipment includes $88,000 of leased equipment. Depreciation
expense on this leased asset for 2015 and 2014 was $12,521 and $12,571, respectively.
|
X |
- References
+ Details
Name: |
fil_FixedAssetsAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13-14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
5. Patent & Patents Filings
|
12 Months Ended |
Sep. 30, 2015 |
Patent Patents Filings |
|
Patent & Patents Filings |
The patent and patents development are recorded at cost and
are being amortized on a straight line basis over a period of seventeen years. The following is a description of the Companys
patent assets.
On August 2, 2011, the Company was awarded U.S. Patent No.
US 7,989,205 B2, titled Cell Culture Media, Kits, and Methods of Use. The Patent is for cell culture media kits for the support
of primary culture of normal non-hematopoietic cells of mesodermal origin suitable for both research and clinical applications.
The Company filed and maintains a continuation (U.S. Serial No. 13/194,900) with additional claims pending
The Company has filed the following additional patents to
extend its intellectual property to encompass additional aspects of the Companys platform processing technologies. To date
the following additional patent filings have been made.
A business method for Collection, Cryogenic Storage and Distribution
of a Biologic Sample Material US Serial No. 13/702,304 filed June 6, 2011with a priority date of June 6, 2010 Systems and Methods
for the Digestion of Adipose Tissue Samples Obtained from a Client for Cryopreservation U.S. Serial No. 13/646,647 filed October
5, 2012 with a priority date of October 6, 2011
Compositions and Methods for Collecting, Washing, Cryopreserving,
Recovering and Return of Lipoaspirates to Physician for Autologous Adipose Transfer Procedures PCT/US13/44621
filed June 6, 2013 with a priority date of June 7, 2013
Stem Cell Based Therapuetic Devices and Methods U.S. Serial
No. 14/196,616 filed March 4, 2014 with a priority dated of March 10, 2013
Autologous Serum for Transport of Isolated Stromal Vascular
Fraction or Adipose Derived Stem Cells US Serial No. 14,250,338 filed in 2014 with a priority date of April 11, 2013
Cell Culture Media, Kits and Methods of Use, US Serial No.
13/1-94/900 continuation of US Serial No. 11/542,863
Human Serum for Cell Culture Medium for Clinical Growth of
Human Adipose Stromal Cells, PCT/US/68350 Filed December 31, 2015 with a priority date of December 31, 2014
|
X |
- References
+ Details
Name: |
fil_PatentPatentsFilingsAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all or part of the information related to intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275
+ Details
Name: |
us-gaap_IntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
6. Debt
|
12 Months Ended |
Sep. 30, 2015 |
Debt |
|
Debt |
As of September 30, 2015, the Company had $607,000 of convertible
notes outstanding. Convertible notes of $159,500 came due on September 30, 2014. The Company is currently in negotiations with
the holders of these notes to convert their notes or to extend their maturity dates. These notes are convertible into common stock
at $0.35 per share. Convertible notes of $447,500 are due at the end of fiscal years 2016 and 2017 and are exercisable into common
stock at $0.30 per share.
During fiscal year 2014, the company issued bridge
notes and received proceeds of $576,000, which were due in fiscal year 2015. The notes are currently in default and due
on demand. Holders of the notes received options to purchase 576,000 shares of common stock at $0.05 per share. The notes are unsecured.
The following table describes the Companys debt outstanding
at September 30, 2015.
Debt |
|
Carrying Value |
|
|
Fair Value |
|
|
Maturity |
|
Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes |
|
$ |
159,500 |
|
|
$ |
159,500 |
|
|
Demand |
|
8.00% |
|
In default |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes |
|
$ |
397,500 |
|
|
$ |
397,500 |
|
|
Fiscal 2016 |
|
8.00% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes |
|
$ |
50,000 |
|
|
$ |
53,000 |
|
|
Fiscal 2017 |
|
8.00% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bridge notes |
|
$ |
576,000 |
|
|
$ |
576,000 |
|
|
Demand |
|
8.00% |
|
In default |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Due to shareholders |
|
$ |
118,347 |
|
|
$ |
118,347 |
|
|
Demand |
|
0.00% |
|
|
|
X |
- References
+ Details
Name: |
fil_DebtAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20,22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
7. Administration Expense
|
12 Months Ended |
Sep. 30, 2015 |
Administration Expense [Abstract] |
|
Administration Expense |
A detail of administrative expenses in the statements of operations
is as follows.
|
|
30-Sep-15 |
|
|
30-Sep-14 |
|
|
|
|
|
|
|
|
Advertising & promotion |
|
$ |
57,383 |
|
|
$ |
110,421 |
|
Automobile |
|
|
2,505 |
|
|
|
5,500 |
|
Bad debt expense |
|
|
16,215 |
|
|
|
0 |
|
Bank fees |
|
|
824 |
|
|
|
567 |
|
Business meetings |
|
|
7,054 |
|
|
|
7,991 |
|
Charitable Contributions |
|
|
12,500 |
|
|
|
65 |
|
Consulting |
|
|
191,510 |
|
|
|
331,943 |
|
Depreciation & amortization |
|
|
40,863 |
|
|
|
40,821 |
|
Dues & subscriptions |
|
|
675 |
|
|
|
3,825 |
|
Insurance |
|
|
2,290 |
|
|
|
4,235 |
|
Travel & meals |
|
|
45,660 |
|
|
|
28,313 |
|
General Office Expenses |
|
|
26,181 |
|
|
|
39,480 |
|
Compensation (Options) |
|
|
568,425 |
|
|
|
539,713 |
|
Rent |
|
|
31,800 |
|
|
|
31,350 |
|
Postage |
|
|
14,890 |
|
|
|
14,662 |
|
Telecommunications |
|
|
10,342 |
|
|
|
9,181 |
|
Utilities |
|
|
4,184 |
|
|
|
2,129 |
|
Web site maintenance |
|
|
5,084 |
|
|
|
1,807 |
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
1,038,385 |
|
|
$ |
1,172,003 |
|
|
X |
- References
+ Details
Name: |
fil_AdministrationExpenseAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the administration expense that an organization incurs not directly tied to a specific function such as manufacturing / production or sales.
+ References
+ Details
Name: |
fil_AdministrationExpenseTextBlock |
Namespace Prefix: |
fil_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
8. Common Stock Issuances
|
12 Months Ended |
Sep. 30, 2015 |
Common Stock Issuances |
|
Common Stock Issuances |
During fiscal year 2014, option holders exercised 170,000
options and the Company issued 170,000 shares of common stock and received proceeds of $24,500.
During fiscal year 2014, holders of convertible notes converted
$152,300 of convertible notes and the Company issued 435,143 shares of common stock.
During fiscal year 2015, debenture holders converted $17,500
of convertible notes into 54,286 shares of common stock.
During fiscal year 2015, officers of the Company exercised
1,460,000 options at $0.01 and received 1,460,000 shares.
During fiscal year 2015, the Company issued 70,000 shares
of common stock to pay $21,000 of the bridge loan discussed in Note 6. As part of this payment, the Company issued 4,542 shares
to pay interest due on the bridge loan.
During fiscal year 2015, the Company issued 175,759 shares of common
stock and received proceeds of $55,000.
During fiscal year 2015, the Company issued 50,000 shares of common
stock to a charitable organization and recognized and expense of $12.500.
|
X |
- References
+ Details
Name: |
fil_EquityAbstract1 |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494
Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
9. Option Issuances
|
12 Months Ended |
Sep. 30, 2015 |
Option Issuances |
|
Option Issuances |
The Company applies ASC 718, Accounting for Stock-Based
Compensation to account for its option issues. Accordingly, all options granted are recorded at fair value using a
generally accepted option pricing model at the date of the grant. The Company uses the Black-Sholes option pricing model to measure
the fair values of its option grants. For purposes of determining the option values at issuance, the fair value of each option
granted is measured at the date of the grant by the option pricing model with the following assumptions:
|
|
2015 |
|
|
2014 |
|
|
|
|
|
|
|
|
Dividend yield |
|
|
0.00 |
% |
|
|
0.00 |
% |
Risk free interest rate |
|
|
0.25 |
% |
|
|
0.25 |
% |
Volatility |
|
|
26.37 |
% |
|
|
48.39 |
% |
The fair values generated by option pricing model may not be
indicative of the future values, if any, that may be received by the option holder.
During fiscal year 2015, the Company issued 3,525,000 options
to employees. As a result, the Company recorded labor expense of $399,432, in its statement of operations.
The following is a summary of common stock options outstanding
at September 30, 2015:
|
|
Amount |
|
|
Wgtd Avg
Exercise Price |
|
|
Wgtd Years
to Maturity |
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2013 |
|
|
6,910,000 |
|
|
$ |
0.18 |
|
|
|
4.16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issues |
|
|
3,816,000 |
|
|
|
|
|
|
|
|
|
Exercises |
|
|
(170,000 |
) |
|
|
|
|
|
|
|
|
Expires |
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2014 |
|
|
10,556,000 |
|
|
$ |
0.21 |
|
|
|
3.74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issues |
|
|
3,525,000 |
|
|
|
|
|
|
|
|
|
Exercises |
|
|
(1,460,000 |
) |
|
|
|
|
|
|
|
|
Expires |
|
|
(300,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2015 |
|
|
12,321,000 |
|
|
$ |
0.21 |
|
|
|
3.41 |
|
|
X |
- References
+ Details
Name: |
fil_OptionIssuancesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14
+ Details
Name: |
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
10. Fair Values of Financial Instruments
|
12 Months Ended |
Sep. 30, 2015 |
Fair Values of Financial Instruments |
|
Fair Values of Financial Instruments |
Fair Value Measurements under generally accepted accounting
principles clarifies the principle that fair value should be based on the assumptions market participants would use when pricing
an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions.
Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy as follows.
Level 1 - Quoted prices in active markets for identical assets
or liabilities.
Level 2 - Observable inputs other than Level 1 prices such
as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions
(less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally
from or corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs to the valuation methodology
that are significant to the measurement of fair value of assets or liabilities.
To the extent that valuation is based on models or inputs
that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain
cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for
disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined
based on the lowest level input that is significant to the fair value measurement.
Cash, accounts receivable, deferred expense, other deposit,
security deposit, accounts payable and accrued expenses, capital lease payable, bridge notes payable, deferred revenue, payable
to shareholder, and advances payable to shareholder in the balance sheet are estimated to approximate fair market value at September
30, 2015 and September 30, 2014 because of their short term nature.
|
X |
- References
+ Details
Name: |
fil_InvestmentsAllOtherInvestmentsAbstract1 |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.
+ References
+ Details
Name: |
us-gaap_FinancialInstrumentsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
11. Commitment And Contingencies
|
12 Months Ended |
Sep. 30, 2015 |
Commitment And Contingencies |
|
Commitments & Contingencies |
Operating Leases - The Company leases laboratory facilities
at the Burlington County College Science Incubator in Burlington, New Jersey. The lease is on a month to month basis
and rents for $2,700 per month. Burlington County College has terminated the lease as of January 15, 2016. The Company has fulfilled
its lease obligation to the college.
The Company plans to execute a new lease for
laboratory facilities in Princeton, New Jersey and plans to move into the new facilities with minimal interruption to
laboratory operations and customer service.
The Company leases office facilities on Meridian Road in Eatontown,
New Jersey. The lease is on a month to month basis and rents for $2,650 per month.
The Company is not party to any litigation against it and is not
aware of any litigation contemplated against it as of September 30, 2015.
|
X |
- References
+ Details
Name: |
fil_CommitmentContingenciesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
12. Concentrations of Credit
|
12 Months Ended |
Sep. 30, 2015 |
Concentrations Of Credit |
|
Concentrations of Credit |
The Company largely relies on the efforts of its Chief Operating
Officer and its Chief Executive Officer. A withdrawal of the efforts of these individuals would have a material adverse affect
on the Companys ability to continue as a going concern.
|
X |
- References
+ Details
Name: |
fil_ConcentrationsOfCreditAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
fil_ConcentrationsOfCreditTextBlock |
Namespace Prefix: |
fil_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
13. Joint Venture
|
12 Months Ended |
Sep. 30, 2015 |
Joint Venture |
|
Joint Venture |
During fiscal year 2014, the Company invested $1,000 in a
joint venture. The joint venture is called Autogenesis Corporation and was incorporated in the state of Florida. The Company and
its two chief executives own 50% of Autogenesis. Autogenesis was formed for the purpose of developing a wound healing protocol.
The Company has no further obligations to Autogenesis and the joint venture will be responsible for its own funding.
|
X |
- References
+ Details
Name: |
fil_JointVentureAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 35 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=49116238&loc=d3e32847-111569
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 35 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=49116238&loc=d3e32787-111569
+ Details
Name: |
us-gaap_EquityMethodInvestmentsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
14. Related Party Transactions
|
12 Months Ended |
Sep. 30, 2015 |
Related Party Transactions [Abstract] |
|
Related Party Transactions |
The other party to the joint venture discussed in Note 13
is controlled by a member of the Companys scientific advisory board.
At September 30, 2015, the company was indebted to its majority
shareholder for advances related to the R&A transaction and additional amounts to the Companys Chairman and Chief Executive
for net advances to the Company of $118,347. The advances are due on demand, are unsecured, and carry no interest rate.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
15. Subsequent Events
|
12 Months Ended |
Sep. 30, 2015 |
Subsequent Events [Abstract] |
|
Subsequent Events |
The Company has made a review of material subsequent
events from September 30, 2015 through the date of this report and found no material subsequent events reportable during this period.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
1. Organization of the Company and Significant Accounting Policies (Policies)
|
12 Months Ended |
Sep. 30, 2015 |
Significant Accounting Policies |
|
Use of Estimates |
The preparation of the financial statements in conformity
with United States generally accepted accounting principles (GAAP) uniformly applied requires management to make
reasonable estimates and assumptions that affect the reported amounts of the assets and liabilities and disclosure of contingent
assets and liabilities and the reported amounts of revenues and expenses at the date of the financial statements and for the period
they include. Actual results may differ from these estimates.
|
Cash |
For the purpose of calculating changes in cash flows, cash includes
all cash balances and highly liquid short-term investments with an original maturity of three months or less.
|
Revenue Recognition |
The Company recognizes tissue processing revenue from the
processing of adipose tissue into usable stem cells once all the procedures have been performed and the client sample has been
stored in the Company cryogenic storage tank. Storage revenues for stored client samples are recognized on an annual basis
on the anniversary date of the storage. Royalties from the licensing of the Companys assets are recognized when earned and
collection of the royalty is reasonable assured. Revenue derived from the sales of collection kits and medium products to Licensees
is recognized upon shipment of the products to the licensee.
|
Long Lived Assets |
The Company reviews for the impairment of long-lived assets
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment
loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition
is less than its carrying amount.
|
Fixed Assets |
Fixed assets are stated at cost. Depreciation expense is computed
using the straight-line method over the estimated useful life of the assets, which is estimated as follows:
|
Office equipment |
5 years |
|
|
Lab equipment & furniture |
7 years |
|
|
Lab software |
5 years |
|
|
Income taxes |
The Company
accounts for income taxes in accordance with generally accepted accounting principles which require an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for differences
between financial statement and income tax bases of assets and liabilities that will result in taxable income or deductible expenses
in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amount expected
to be realized. Income tax expense is the tax payable or refundable for the period adjusted for the change during the period in
deferred tax assets and liabilities.
The Company follows the accounting requirements associated
with uncertainty in income taxes using the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes. Using
that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the positions
will be sustained upon examination by the tax authorities. It also provides guidance for derecognition, classification, interest
and penalties, accounting in interim periods, disclosure and transition. As of September 30, 2015 and September 30, 2014, the
Company has no uncertain tax positions that
|
Recently Issued Accounting Pronouncement |
There are no recently issued accounting pronouncements that have
a material impact on the Companys financial statements.
|
X |
- References
+ Details
Name: |
fil_SignificantAccountingPoliciesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -SubTopic 10 -Section 05 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 203 -Paragraph 02-03
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 05 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51717228&loc=d3e202-110218
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section CC -Subsection 3
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 05 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 740 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1
+ Details
Name: |
us-gaap_RevenueRecognitionPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
fil_OrganizationOfCompanyAndSignificantAccountingPoliciesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
fil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock |
Namespace Prefix: |
fil_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
fil_LossPerShareTablesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
4. Fixed Assets (Tables)
|
12 Months Ended |
Sep. 30, 2015 |
Fixed Assets Tables |
|
Schedule of summary of Fixed Assets |
|
|
30-Sep-15 |
|
|
30-Sep-14 |
|
|
|
|
|
|
|
|
Office equipment |
|
$ |
26,637 |
|
|
$ |
26,637 |
|
Lab furniture |
|
|
642 |
|
|
|
642 |
|
Office furniture |
|
|
999 |
|
|
|
999 |
|
Lab equipment |
|
|
254,054 |
|
|
|
254,054 |
|
Lab software |
|
|
123,000 |
|
|
|
123,000 |
|
Accumulated depreciation |
|
|
(194,018 |
) |
|
|
(155,150 |
) |
|
|
|
|
|
|
|
|
|
Fixed assets- net |
|
$ |
211,314 |
|
|
$ |
250,182 |
|
|
X |
- References
+ Details
Name: |
fil_FixedAssetsTablesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph b -Article 5
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
6. Debt (Tables)
|
12 Months Ended |
Sep. 30, 2015 |
Debt Tables |
|
Schedule of Debt Outstanding |
Debt |
|
Carrying Value |
|
|
Fair Value |
|
|
Maturity |
|
Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes |
|
$ |
159,500 |
|
|
$ |
159,500 |
|
|
Demand |
|
8.00% |
|
In default |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes |
|
$ |
397,500 |
|
|
$ |
397,500 |
|
|
Fiscal 2016 |
|
8.00% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes |
|
$ |
50,000 |
|
|
$ |
53,000 |
|
|
Fiscal 2017 |
|
8.00% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bridge notes |
|
$ |
576,000 |
|
|
$ |
576,000 |
|
|
Demand |
|
8.00% |
|
In default |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Due to shareholders |
|
$ |
118,347 |
|
|
$ |
118,347 |
|
|
Demand |
|
0.00% |
|
|
|
X |
- References
+ Details
Name: |
fil_DebtTablesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(e),(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644
+ Details
Name: |
us-gaap_ScheduleOfDebtInstrumentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
7. Administration Expense (Tables)
|
12 Months Ended |
Sep. 30, 2015 |
Administration Expense [Abstract] |
|
Schedule of administrative expenses |
|
|
30-Sep-15 |
|
|
30-Sep-14 |
|
|
|
|
|
|
|
|
Advertising & promotion |
|
$ |
57,383 |
|
|
$ |
110,421 |
|
Automobile |
|
|
2,505 |
|
|
|
5,500 |
|
Bad debt expense |
|
|
16,215 |
|
|
|
0 |
|
Bank fees |
|
|
824 |
|
|
|
567 |
|
Business meetings |
|
|
7,054 |
|
|
|
7,991 |
|
Charitable Contributions |
|
|
12,500 |
|
|
|
65 |
|
Consulting |
|
|
191,510 |
|
|
|
331,943 |
|
Depreciation & amortization |
|
|
40,863 |
|
|
|
40,821 |
|
Dues & subscriptions |
|
|
675 |
|
|
|
3,825 |
|
Insurance |
|
|
2,290 |
|
|
|
4,235 |
|
Travel & meals |
|
|
45,660 |
|
|
|
28,313 |
|
General Office Expenses |
|
|
26,181 |
|
|
|
39,480 |
|
Compensation (Options) |
|
|
568,425 |
|
|
|
539,713 |
|
Rent |
|
|
31,800 |
|
|
|
31,350 |
|
Postage |
|
|
14,890 |
|
|
|
14,662 |
|
Telecommunications |
|
|
10,342 |
|
|
|
9,181 |
|
Utilities |
|
|
4,184 |
|
|
|
2,129 |
|
Web site maintenance |
|
|
5,084 |
|
|
|
1,807 |
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
1,038,385 |
|
|
$ |
1,172,003 |
|
|
X |
- References
+ Details
Name: |
fil_AdministrationExpenseAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
9. Option Issuances (Tables)
|
12 Months Ended |
Sep. 30, 2015 |
Option Issuances Tables |
|
Schedule of assumptions for determining the fair value of option value at issuance |
|
|
2015 |
|
|
2014 |
|
|
|
|
|
|
|
|
Dividend yield |
|
|
0.00 |
% |
|
|
0.00 |
% |
Risk free interest rate |
|
|
0.25 |
% |
|
|
0.25 |
% |
Volatility |
|
|
26.37 |
% |
|
|
48.39 |
% |
|
Schedule of summary of common stock options outstanding |
|
|
Amount |
|
|
Wgtd Avg
Exercise Price |
|
|
Wgtd Years
to Maturity |
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2013 |
|
|
6,910,000 |
|
|
$ |
0.18 |
|
|
|
4.16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issues |
|
|
3,816,000 |
|
|
|
|
|
|
|
|
|
Exercises |
|
|
(170,000 |
) |
|
|
|
|
|
|
|
|
Expires |
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2014 |
|
|
10,556,000 |
|
|
$ |
0.21 |
|
|
|
3.74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issues |
|
|
3,525,000 |
|
|
|
|
|
|
|
|
|
Exercises |
|
|
(1,460,000 |
) |
|
|
|
|
|
|
|
|
Expires |
|
|
(300,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2015 |
|
|
12,321,000 |
|
|
$ |
0.21 |
|
|
|
3.41 |
|
|
X |
- References
+ Details
Name: |
fil_OptionIssuancesTablesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor each plan, identification of the award pricing model or other valuation method used in calculating the weighted average fair values disclosed. The model is also used to calculate the compensation expense that is shown within the balance sheet, income statement, and cash flow. Examples of valuation techniques are lattice models (binomial model), closed-form models (Black-Scholes-Merton formula), and a Monte Carlo simulation technique. Fair value is the amount at which an asset or liability could be bought or incurred or sold or settled in a current transaction between willing parties, that is, other than in a forced or liquidation sale. May include disclosures about the assumptions underlying application of the method selected.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- DefinitionDescribes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 35 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51661791&loc=d3e1205-110223
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_OfficeEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=fil_LabEquipmentAmpFurnitureMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=fil_LabSoftwareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- References
+ Details
Name: |
fil_OrganizationOfCompanyAndSignificantAccountingPoliciesAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of equity interests issued or issuable to acquire entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details
Name: |
us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
3. Loss Per Share - Summary of net loss per share (Details) - USD ($)
|
12 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Earnings Per Share [Abstract] |
|
|
Net loss |
$ (1,379,480)
|
$ (2,088,149)
|
Weighted average shares outstanding |
33,044,333
|
32,607,073
|
Basic & fully diluted net loss per common share: |
|
|
Net gain (loss) |
$ (.04)
|
$ (0.06)
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDilutedAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
+ Details
Name: |
us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
4. Fixed Assets - Summary of Fixed Assets (Details) - USD ($)
|
Sep. 30, 2015 |
Sep. 30, 2014 |
Property, Plant and Equipment [Line Items] |
|
|
Accumulated depreciation |
$ (194,018)
|
$ (155,150)
|
Fixed assets- net |
211,314
|
250,182
|
Office Equipment |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Accumulated depreciation |
26,637
|
26,637
|
Lab Furniture |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Accumulated depreciation |
642
|
642
|
Office Furniture |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Accumulated depreciation |
999
|
999
|
Lab Equipment |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Accumulated depreciation |
254,054
|
254,054
|
Lab Software |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Accumulated depreciation |
$ 123,000
|
$ 123,000
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=fil_LaboratoryFurnitureMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=fil_LaboratoryEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=fil_LaboratorySoftwareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionAmount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45014-112735
+ Details
Name: |
us-gaap_CapitalLeasedAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe charge for the use of long-lived depreciable capital leased assets for the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 980 -SubTopic 840 -Section 55 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501752&loc=d3e56872-110439
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45031-112735
+ Details
Name: |
us-gaap_CapitalLeasesIncomeStatementAmortizationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
6. Debt - Summary of debt outstanding (Details)
|
12 Months Ended |
Sep. 30, 2015
USD ($)
|
Convertible Notes |
|
Debt Instrument [Line Items] |
|
Carrying Value |
$ 159,500
|
Fair Value |
$ 159,500
|
Maturity |
Demand
|
Rate |
8.00%
|
Convertible Notes |
|
Debt Instrument [Line Items] |
|
Carrying Value |
$ 397,500
|
Fair Value |
$ 397,500
|
Maturity |
Fiscal 2016
|
Rate |
8.00%
|
Convertible Notes |
|
Debt Instrument [Line Items] |
|
Carrying Value |
$ 50,000
|
Fair Value |
$ 53,000
|
Maturity |
Fiscal 2017
|
Rate |
8.00%
|
Bridge Notes |
|
Debt Instrument [Line Items] |
|
Carrying Value |
$ 576,000
|
Fair Value |
$ 576,000
|
Maturity |
Demand
|
Rate |
8.00%
|
Due To Shareholder |
|
Debt Instrument [Line Items] |
|
Carrying Value |
$ 118,347
|
Fair Value |
$ 118,347
|
Maturity |
Demand
|
Rate |
0.00%
|
X |
- DefinitionAmount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 9
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13476-108611
+ Details
Name: |
us-gaap_DebtInstrumentFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=fil_ConvertibleNoteOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=fil_ConvertibleNoteTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=fil_BridgeNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=fil_DueToShareholderMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- Definition
+ References
+ Details
Name: |
fil_ConversionOfStockSharesIssuedParValue1 |
Namespace Prefix: |
fil_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Definition
+ References
+ Details
Name: |
fil_ConvertibleNotesOutstanding |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresents exercise price of convertible notes.
+ References
+ Details
Name: |
fil_DebtInstrumentExercisePrice |
Namespace Prefix: |
fil_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent debt instrument maturity date.
+ References
+ Details
Name: |
fil_DebtInstrumentMaturityDateTwo |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details
Name: |
us-gaap_ConversionOfStockSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=fil_BridgeNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
7. Administration Expense - Summary of administrative expenses (Details) - USD ($)
|
12 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Administration Expense [Abstract] |
|
|
Advertising & promotion |
$ 57,383
|
$ 110,421
|
Automobile |
2,505
|
5,500
|
Bad debt expense |
16,215
|
0
|
Bank fees |
824
|
567
|
Business meetings |
7,054
|
7,991
|
Charitable Contributions |
12,500
|
65
|
Consulting |
191,510
|
331,943
|
Depreciation & amortization |
40,864
|
40,821
|
Dues & subscriptions |
675
|
3,825
|
Insurance |
2,290
|
4,235
|
Travel & meals |
45,660
|
28,313
|
General Office Expenses |
26,181
|
39,480
|
Compensation (Options) |
568,425
|
539,713
|
Rent |
31,800
|
31,350
|
Postage |
14,890
|
14,662
|
Telecommunications |
10,342
|
9,181
|
Utilities |
4,184
|
2,129
|
Web site maintenance |
5,084
|
1,807
|
Total |
$ 1,038,385
|
$ 1,172,003
|
X |
- References
+ Details
Name: |
fil_AdministrationExpenseAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of automobile expenses.
+ References
+ Details
Name: |
fil_AutomobileExpenses |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of business meetings expenses.
+ References
+ Details
Name: |
fil_BusinessMeetingsExpenses |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_CharitableContributions |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRepresents amount of dues and subscriptions expenses.
+ References
+ Details
Name: |
fil_DuesAndSubscriptionsExpenses |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe total expense recognized in the period for insurance.
+ References
+ Details
Name: |
fil_InsuranceExpenses |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense in the period for communications and data processing expense.
+ References
+ Details
Name: |
fil_TelecommunicationsExpenses |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense in the period for website expenses.
+ References
+ Details
Name: |
fil_WebsiteMaintenanceExpenses |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
+ Details
Name: |
us-gaap_LeaseAndRentalExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_LegalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe total expense recognized in the period for promotion, public relations, and brand or product advertising.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_MarketingAndAdvertisingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe sum of expenses not otherwise specified in the taxonomy for managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OtherGeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of general expenses not normally included in Other Operating Costs and Expenses.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.6) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OtherGeneralExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense associated with postage.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.14) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_PostageExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.5) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionExpenses incurred for travel and entertainment during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_TravelAndEntertainmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionUtilities costs incurred during the reporting period for services, such as water, sewer, gas, electricity and telephone required to operate a building.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_UtilitiesCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.3.1.900
8. Common Stock Issuances (Detail Textuals) - USD ($)
|
12 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Stockholders' Equity Note [Abstract] |
|
|
Number of common stock issued (in shares) |
175,759
|
170,000
|
Proceeds from issuance of common stock |
$ 55,000
|
$ 24,500
|
Convertible note exercise amount |
$ 17,500
|
$ 152,300
|
Convertible note exercise amount (in shares) |
54,286
|
435,143
|
Options exercised |
1,460,000
|
|
Option exercise price |
$ .01
|
|
Bridge note amount |
$ 21,000
|
|
Shares issued to pay bridge loan |
70,000
|
|
Shares issued to pay bridge loan interest |
4,542
|
|
X |
- DefinitionRepresents debt instrument exercise amount.
+ References
+ Details
Name: |
fil_ConvertibleNoteExerciseAmount |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesIssuedToPayBridgeLoanInterest |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesIssuedToPayBridgeNote |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SharesIssuedToPayBridgeNoteShares |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise or strike price stated in the contract for options indexed to the issuer's equity shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(1) -URI http://asc.fasb.org/extlink&oid=6940734&loc=d3e22047-110879
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 5 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=6445032&loc=d3e90205-114008
+ Details
Name: |
us-gaap_OptionIndexedToIssuersEquityStrikePrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityNoteAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
9. Option Issuances - Summary of Common Stock Options Outstanding (Details) {Stockholders'Equity} - $ / shares
|
12 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Summary of Common Stock Options Outstanding: |
|
|
Outstanding |
10,556,000
|
6,910,000
|
Issues |
3,525,000
|
3,816,000
|
Exercises |
(1,460,000)
|
(170,000)
|
Expires |
(300,000)
|
0
|
Outstanding |
12,321,000
|
10,556,000
|
Weighted average exercise price, outstanding beginning |
$ 0.21
|
$ 0.18
|
Weighted average exercise price, outstanding ending |
$ .21
|
$ 0.21
|
Weighted years to maturity outstanding beginning |
3 years 8 months 27 days
|
4 years 1 month 28 days
|
Weighted years to maturity outstanding |
3 years 4 months 28 days
|
3 years 8 months 27 days
|
X |
- References
+ Details
Name: |
fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
fil_SummaryOfCommonStockOptionsOutstandingAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
fil_WeightedYearsToMaturityOutstandingBeginning |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(4) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- Definition
+ References
+ Details
Name: |
fil_InvestmentInJointVenture |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
fil_JointVentureDetailTextualsAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
fil_RelatedPartyTransactionsDetailTextualsAbstract |
Namespace Prefix: |
fil_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2023 to Jul 2024